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Abstract
RNA-Seq and gene expression microarrays provide comprehensive profiles of gene
activity, but lack of reproducibility has hindered their application. A key challenge
in the data analysis is the normalization of gene expression levels, which is currently
performed following the implicit assumption that most genes are not differentially
expressed. Here, we present a mathematical approach to normalization that makes
no assumption of this sort. We have found that variation in gene expression is much
larger than currently believed, and that it can be measured with available assays.
Our results also explain, at least partially, the reproducibility problems encountered
in transcriptomics studies. We expect that this improvement in detection will help
efforts to realize the full potential of gene expression profiling, especially in analyses
of cellular processes involving complex modulations of gene expression.
Keywords
differential gene expression
gene expression microarrays
RNA-Seq
normalization of high-throughput data
Abbreviations
DEG: Differentially Expressed Gene
FDR: False Discovery Rate
MedianCD normalization: Median Condition-Decomposition normalization
SVCD normalization: Standard-Vector Condition-Decomposition normalization
2
Introduction
Since the discovery of DNA structure by Watson and Crick, molecular biology has pro-
gressed increasingly fast, with rapid advances in sequencing and related genomic technolo-
gies. Among these, DNA microarrays and RNA-Seq have been widely adopted to obtain
gene expression profiles, by measuring the concentration of tens of thousands of mRNA
molecules in single assays [Schena et al., 1995; Lockhart et al., 1996; Duggan et al., 1999;
Mortazavi et al., 2008; Wang et al., 2009]. Despite their enormous potential [Golub et al.,
1999; van ’t Veer et al., 2002; Ivanova et al., 2002; Chi et al., 2003], problems of repro-
ducibility and reliability [Tan et al., 2003; Frantz, 2005; Couzin, 2006] have discouraged
their use in some areas, e.g. biomedicine [Michiels et al., 2005; Weigelt and Reis-Filho,
2010; Brettingham-Moore et al., 2011; Boutros, 2015].
The normalization of gene expression, which is required to set a common reference level
among samples [Irizarry et al., 2003; Tarca et al., 2006; Garber et al., 2011; Conesa
et al., 2016], has been reported to be problematic, affecting the reproducibility of results
with both microarray [Shi et al., 2006; Shippy et al., 2006; Draghici et al., 2006] and
RNA-Seq [Bullard et al., 2010; Dillies et al., 2013; Su et al., 2014; Lin et al., 2016].
Batch effects and their influence on normalization have recently received a great deal of
attention [Leek et al., 2010; Reese et al., 2013; Li et al., 2014], resulting in approaches
aiming to remove unwanted technical variation caused by differences between batches of
samples or by other sources of expression heterogeneity [Listgarten et al., 2010; Gagnon-
Bartsch and Speed, 2012; Risso et al., 2014]. A different issue, however, is the underlying
assumption made by the most widely used normalization methods to date, such as Median
and Quantile normalization [Bolstad et al., 2003] for microarrays, or RPKM (Reads Per
Kilobase per Million mapped reads) [Mortazavi et al., 2008], TMM (Trimmed Mean of M-
values) [Robinson and Oshlack, 2010], and DESeq [Anders and Huber, 2010] normalization
for RNA-Seq, which posit that all or most genes are not differentially expressed [van de
Peppel et al., 2003; Hannah et al., 2008; Love´n et al., 2012; Dillies et al., 2013; Hicks
and Irizarry, 2015]. Although it may seem reasonable for many applications, this lack-of-
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variation assumption has not been confirmed. Moreover, results obtained with external
controls [van de Peppel et al., 2003; Hannah et al., 2005, 2008; Love´n et al., 2012] or with
RT-qPCR [Shi et al., 2006; Bullard et al., 2010] suggest that it may not be valid.
Some methods have been proposed to address this issue, based on the use of spike-ins
[van de Peppel et al., 2003; Hannah et al., 2008; Love´n et al., 2012], negative control
probes (SQN, Subset Quantile normalization) [Wu and Aryee, 2010], or negative control
genes (RUV-2, Remove Unwanted Variation, 2-step) [Gagnon-Bartsch and Speed, 2012].
These methods use external or internal controls that are known a priori not to be differen-
tially expressed [Lippa et al., 2010]. Their applicability, however, has been limited by this
requirement of a priori knowledge, which is rarely available for a sufficiently large number
of controls. In addition, other methods have been proposed to address the lack-of-variation
assumption by identifying a subset of non-differentially expressed genes from the assay
data, such as Cross-Correlation normalization [Chua et al., 2006], LVS (Least-Variant
Set) normalization [Calza et al., 2008], and NVAS (Nonparametric Variable Selection and
Approximation) normalization [Ni et al., 2008]. While LVS normalization requires setting
in advance a number for the fraction of genes to be considered as non-differentially ex-
pressed, with values in the range 40–60% [Calza et al., 2008], Cross-Correlation and NVAS
normalization are expected to degrade in performance when more than 50% of genes are
differentially expressed [Chua et al., 2006; Ni et al., 2008]. More recently, CrossNorm has
been introduced [Cheng et al., 2016], based on the mixture of gene expression distribu-
tions from the experimental conditions. This method, however, has been proposed for
two experimental conditions, and specially for paired samples. The extension of this ap-
proach to experimental designs with unpaired samples and more than a few experimental
conditions would lead, as far as we can hypothesize, to an unmanageable size of the data
matrix to process.
Thus, to clarify and overcome the limitations imposed by the lack-of-variation assumption,
we have developed an approach to normalization that does not assume lack-of-variation
and that is suitable to most real-world applications. Hence, we aimed to avoid the need
of spike-ins, a priori knowledge of control genes, or assumptions on the number of dif-
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ferentially expressed genes. The analysis of several gene expression datasets using this
approach confirmed that our methods reached these goals. Furthermore, our results show
that assuming lack-of-variation can severely undermine the detection of gene expression
variation in real assays. We have found that large numbers of differentially expressed
genes, with substantial expression changes, are missed or misidentified when data are
normalized with methods that assume lack-of-variation.
Results
E. crypticus and Synthetic Datasets
A large gene expression dataset was obtained from biological triplicates of Enchytraeus
crypticus (a globally distributed soil organism used in standard ecotoxicity tests), sampled
under 51 experimental conditions (42 treatments and 9 controls), involving exposure to
several substances, at several concentrations and durations according to a factorial design
(Supplementary Table S1). Gene expression was measured using a customized high-
density oligonucleotide microarray [Castro-Ferreira et al., 2014], resulting in a dataset
with 18,339 gene probes featuring good hybridization signal in all 153 samples. Taking
into account the design of the microarray [Castro-Ferreira et al., 2014], we refer to these
gene probes as genes in what follows.
To further explore and compare outcomes between normalization methods, two synthetic
random datasets were built and analyzed. One of them was generated with identical means
and variances gene-by-gene to the real E. crypticus dataset, and under the assumption
that no gene was differentially expressed. In addition, normalization factors were applied,
equal to those obtained from the real dataset. Thus, this synthetic dataset was similar
to the real one, while complying by construction with the lack-of-variation assumption.
The other synthetic dataset was also generated with comparable means and variances to
the real dataset and with normalization factors, but in this case differential expression
was added. Depending on the experimental condition, several numbers of differentially
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expressed genes and ratios between over- and under-expressed genes were introduced
(see Methods). Together, these synthetic datasets with and without differential gene
expression represent, respectively, the alternative and null hypotheses for a statistical test
of differential gene expression.
Normalization Methods
The gene expression datasets were normalized with four methods. Two of these methods
are the most widely used procedures for microarrays, namely Median (or Scale) normal-
ization and Quantile normalization [Bolstad et al., 2003]. (Note that current methods
of normalization for RNA-Seq, such as RPKM [Mortazavi et al., 2008], TMM [Robin-
son and Oshlack, 2010], and DESeq [Anders and Huber, 2010], perform between-sample
normalization by introducing a scaling per sample obtained with some form of mean or
median, using all or a large set of genes. Thus their performance, in what concerns
the issues addressed here, is expected to be similar to that of Median normalization for
microarrays.)
The other two normalization methods were developed for this study, they being called Me-
dian Condition-Decomposition normalization and Standard-Vector Condition-Decomposition
normalization, respectively MedianCD and SVCD normalization in what follows.
With the exception of Quantile normalization, all used methods apply a multiplicative
factor to the expression levels of each sample, equivalent to the addition of a number in the
usual log2-scale for gene expression levels. Solving the normalization problem consists of
finding these correction factors. This problem can be exactly and linearly decomposed into
several sub-problems: one within-condition normalization for each experimental condition
and one final between-condition normalization for the condition averages (see Methods).
In the within-condition normalizations, the samples (replicates) subjected to each ex-
perimental condition are normalized separately, whereas in the final between-condition
normalization average levels for all conditions are normalized together. Because there
are no genes with differential expression in any of the within-condition normalizations,
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the lack-of-variation assumption only affects the final between-condition normalization.
The assumption is avoided by using, in this normalization, expression levels only from
no-variation genes, defined as genes that show no evidence of differential expression under
a statistical test. An important detail is that the within-condition normalizations ensure
good estimates of the within-condition variances, which are required by the statistical
test for identifying no-variation genes. This requisite also implies that a minimum of two
samples is required per experimental condition. Both methods of normalization proposed
here, MedianCD and SVCD normalization, follow this condition-decomposition approach.
With MedianCD normalization, all normalizations are performed with median values, as
in conventional Median normalization, but only no-variation genes are employed in the
between-condition step. Otherwise, if all genes were used in this final step, the resulting
total normalization factors would be exactly the same as those obtained with conventional
Median normalization.
For SVCD normalization, a vectorial procedure was developed to carry out each normal-
ization step, called Standard-Vector normalization. The samples of any experimental con-
dition, in a properly normalized dataset, must be exchangeable. In mathematical terms,
the expression levels of each gene can be considered as an s-dimensional vector, where s is
the number of samples for the experimental condition. After standardization (mean sub-
traction and variance scaling), these standard vectors are located in a (s−2)-dimensional
hypersphere. The exchangeability mentioned above implies that, when properly normal-
ized, the distribution of standard vectors must be invariant with respect to permutations
of the samples and must have zero expected value. These properties allow to obtain a
robust estimator of the normalization factors, under fairly general assumptions that do
not imply any particular distribution of gene expression (see Methods).
It is worth mentioning that the limit case when the number of samples is two (s = 2)
represents a degenerate case for Standard-Vector normalization, in which the space of
standard vectors reduces to a 0-dimensional space with only two points. In this degenerate
case, Standard-Vector normalization is equivalent to global Loess normalization [Yang
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et al., 2002; Smyth and Speed, 2003], i.e. Loess normalization without correction for non-
linearities with respect to the level of gene expression or microarray print-tips. In this
sense, Standard-Vector normalization is a generalization to any number of samples of the
approach underlying the different types of Loess normalization.
Normalization Results
Figure 1 displays the results of applying the four normalization methods to the real and
two synthetic datasets. Each panel shows the interquartile range of expression levels for
the 153 samples, grouped in triplicates exposed to each experimental condition. Both
Median and Quantile normalization (second and third rows) yielded similar outputs for
the three datasets. In contrast, MedianCD and SVCD normalization (fourth and fifth
rows) detected much greater variation between conditions in the real dataset and the
synthetic dataset with differential gene expression. Conventional Median normalization
makes, by design, the median of all samples to be the same, while Quantile normalization
makes the full distribution of gene expression of all samples to be the same. Hence, if
there were differences in medians or distributions between experimental conditions, both
methods would have removed them. Such variation was indeed present in the synthetic
dataset with differential gene expression (Fig. 1k,n), and hence we can hypothesize the
same for the real dataset (Fig. 1j,m).
Influence of No-Variation Genes on Normalization
To clarify how MedianCD and SVCD normalization preserved the variation between con-
ditions, we studied the influence of the choice of no-variation genes in the final between-
condition normalization. To this end, we obtained the between-condition variation as
a function of the number of no-variation genes, in two families of cases. In one family,
no-variation genes were chosen in decreasing order of p-values from the statistical test
used to analyze variation between conditions. In the other family, genes were chosen at
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random. The first option was similar to the approach implemented to obtain the results
presented in Fig. 1j–o, with the difference that, there, the no-variation genes were chosen
automatically, by a subsequent statistical test performed on the distribution of p-values
(see Methods).
For the real dataset (Fig. 2a), the random choice of genes resulted in n−1/2 decays (n
being the number of chosen genes), followed by a plateau. The n−1/2 decays reflect the
error in the estimation of normalization factors. Selecting the genes by decreasing p-
values, however, yielded a completely different result. Up to a certain number of genes,
the variance remained similar, but for larger numbers of genes the variance dropped
rapidly. Figure 2a shows, therefore, that between-condition variation was removed as
soon as the between-condition normalizations used genes that changed in expression level
across experimental conditions. The big circles in Fig. 2a indicate the working points
of the normalizations used for the results displayed in Fig. 1j,m. In fact, these points
slightly underestimated the variation between conditions. Although the statistical test
for identifying no-variation genes ensured that no evidence of variation was found, the
expression of some selected genes varied across conditions.
The results obtained for the synthetic dataset with differential gene expression (Fig. 2b)
were qualitatively similar to those of the real dataset, but with two important differences.
The amount of between-condition variation detected (by selecting no-variation genes by
decreasing p-values) was smaller than with the real dataset, implying that the real dataset
had larger differential gene expression. Additionally, the variation detected in the syn-
thetic dataset had a simpler dependency on the number of genes, an indication that the
differential gene expression introduced in the synthetic dataset had a simpler structure
than that of the real dataset.
Figure 2c shows the results for the synthetic dataset without differential gene expression.
There were no plateaus when no-variation genes were chosen randomly, only n−1/2 decays,
and differences were small when no-variation genes were selected by decreasing p-values.
Big circles show that the working points of Fig. 1l,o were selected with all available genes
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as no-variation genes, which is the optimum choice when there is no differential gene
expression.
Overall, Fig. 2 shows that the between-condition variation displayed in Fig. 1j,k,m,n is
not an artifact caused by using an exceedingly small or extremely particular set of genes
in the final between-condition normalization, but that this variation originated from the
datasets. The positions of the big circles in Fig. 2 highlight the good performance of the
statistical approach for choosing no-variation genes in the normalizations carried out for
Fig. 1j–o. Besides, the residual variation displayed by the n−1/2 decays implies that, as
estimators of the normalization factors, SVCD normalization features smaller error than
MedianCD normalization.
Differential Gene Expression
In what follows, we call detected positives the differentially expressed genes (DEGs) result-
ing from the statistical analyses, treatment positives the DEGs introduced in the synthetic
dataset with differential gene expression, true positives the detected positives which were
also treatment positives, and false positives the detected positives which were not treat-
ment positives. Corresponding terms for negatives refer to genes which were not DEGs.
Figure 3 shows the numbers of DEGs detected in the real and synthetic datasets, for each
of the 42 experimental treatments compared to the corresponding control (Supplementary
Table S2), after normalizing with the four methods. For the real dataset (Fig. 3a), the
number of DEGs identified after MedianCD and SVCD normalization were much larger
for most treatments, in some cases by more than one order of magnitude. For the synthetic
dataset with differential gene expression (Fig. 3b), results were qualitatively similar, but
with less differential gene expression detected, consistently with Fig. 2a,b. The number of
treatment positives can be displayed in this case (empty black down triangles, Fig. 3b),
showing a better correlation, with MedianCD and SVCD normalization, between the
number of treatment positives and detected positives. For the synthetic dataset without
differential gene expression (Fig. 3c), no DEG was found but for one or two DEGs in
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two conditions. Given that the false discovery rate was controlled to be less than 5% per
treatment, this is expected to happen when evaluating 42 treatments.
Figure 3a reports, for the real dataset, statistically significant changes of gene expression,
that is, changes that cannot be explained by chance. Equally important is the effect size,
i.e. the scale of detected variation in DEGs, which is displayed by Fig. 4. The boxplots
show absolute fold changes of expression level for all DEGs detected after applying each
normalization method. MedianCD and SVCD normalization allowed to detect smaller
changes of gene expression, which were otherwise missed when using Median and Quantile
normalization. This differential gene expression detected with MedianCD and SVCD
normalization can hardly be considered negligible, given that, for all treatments, the
interquartile range of absolute fold changes was above 1.5-fold, and, for more than 28
(67%) treatments, the median absolute fold change was greater than 2-fold. Interestingly,
the scale of differential gene expression detected with MedianCD and SVCD normalization
in this assay is of similar magnitude to those reported by studies of global mRNA changes
using external controls with microarrays and/or RNA-Seq [van de Peppel et al., 2003;
Love´n et al., 2012].
Figure 5 displays the balance of differential gene expression, i.e. the comparison between
the number of over- and under-expressed genes, for the real dataset. The quantity in the
y-axes is the mean of an indicator variable B, which assigns +1 to each over-expressed
DEG and −1 to each under-expressed DEG. Hence, balance of differential gene expres-
sion corresponds to B = 0, all DEGs over-expressed to B = +1, and, for example, 60%
DEGs under-expressed to B = −0.2. As discussed below, and as it has been reported
before [Irizarry et al., 2006; Calza et al., 2008; Ni et al., 2008; Zhu et al., 2010], the
balance of differential gene expression has a strong impact on the performance of normal-
ization methods. Figure 5 shows that, regardless of the normalization method used, the
unbalance of differential gene expression detected in the real dataset was substantial for
most conditions. Detected unbalances were (in absolute value) larger with MedianCD and
SVCD normalization, in both cases with more than 30 (71%) treatments having |B| > 0.5,
that is, more than 75% of over- or under-expressed genes. Moreover, the differences be-
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tween the unbalances detected with Median and Quantile normalization, on one hand,
and MedianCD and SVCD normalization, on the other, were specially notorious for the
treatments with more DEGs (treatments 26–42, Fig. 3a). In those cases, Median and
Quantile normalization resulted in the smallest detected unbalances, whereas MedianCD
and SVCD normalization yielded the largest ones, with values near B = ±1 for all but
two treatments.
True differential expression was known, by construction, for the synthetic dataset with
differential gene expression. Thus, Fig. 6 shows for this dataset the true positive rate
(ratio between true positives and treatment positives, also known as statistical power or
sensitivity) and the false discovery rate (FDR, ratio between false positives and detected
positives). With conditions 1 to 20, which correspond to those conditions with less than
approximately 10% of treatment positives (Fig. 3b, empty black down triangles), the
true positive rate was similarly low for all normalizations. Regarding the FDR, when
the (total) number of detected positives was up to a few tens, variability of the FDR
around the target bound at 0.05 is to be expected, given that the bound is defined over an
average of repetitions of the multiple-hypothesis test. Yet, the FDR obtained after Median
and Quantile normalization was higher than the 0.05 bound for most conditions. More
striking, however, was the behavior for conditions 21 to 42 (more than 10% of treatment
positives). The true positive rates obtained after Median and Quantile normalization
were much lower than those obtained with MedianCD and SVCD normalization, while
the FDR after Median and Quantile normalization was clearly over the bound at 0.05.
In comparison, MedianCD and SVCD normalization, besides offering better sensitivity of
differential gene expression, maintained the FDR consistently below the desired bound.
Figure 7 further explores these results, by representing the true positive rate and false
discovery rate (FDR) as a function of the unbalance between over- and under-expressed
genes. Figure 7 shows that the unbalance of differential gene expression was a key factor
in the results obtained with Median and Quantile normalization. When most DEGs were
over- or under-expressed, both the true positive rate and FDR degraded markedly after
using Median or Quantile normalization. In contrast, the true positive rate and FDR
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were not affected by the unbalance of differential gene expression when using MedianCD
or SVCD normalization.
Concerning the identification of no-variation genes, both MedianCD and SVCD normal-
ization performed well. In the synthetic dataset without differential gene expression, both
methods identified all genes as no-variation genes, which is the best possible result. In the
synthetic dataset with differential gene expression, 1,834 genes (10% of a total of 18,339
genes) were, by construction, negatives across all treatments. MedianCD and SVCD nor-
malization detected, respectively, 1,723 and 1,827 no-variation genes, among which 96.9%
and 95.2% were true negatives.
Analysis of the Golden Spike and Platinum Spike Datasets
To provide additional evidence of the performance of MedianCD and SVCD normalization,
we analyzed the Golden Spike [Choe et al., 2005] and Platinum Spike [Zhu et al., 2010]
datasets. Both of them are artificial real datasets, the largest ones for which true DEGs
are known. Hence, they have been widely used to benchmark normalization methods
[Choe et al., 2005; Schuster et al., 2007; Pearson, 2008; Calza et al., 2008; Ni et al., 2008;
Zhu et al., 2010; Cheng et al., 2016].
The design of the Golden Spike dataset was questioned for reasons concerning, among
others, the anomalous null distribution of p-values, the lack of biological replicates, and
the high concentration of spike-ins [Dabney and Storey, 2006; Irizarry et al., 2006; Gaile
and Miecznikowski, 2007]. Nevertheless, this dataset is worth considering here because
it challenges what we claim are key capabilities of our approach, that is, to correctly
normalize gene expression data when many genes are differentially expressed, even with
large unbalance between over- and under-expression. This dataset consists of microarray
data obtained with the Affymetrix GeneChip DrosGenome1, with two experimental con-
ditions and three technical replicates per condition. Excluding Affymetrix internal control
probes, the dataset contains a total of 13,966 gene probe sets, of which 3,876 were spiked-
in, which we call known in what follows. Among these, 1,328 (34.3%) were over-expressed
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(known positives) to varying degrees between 1.1- and 4-fold, while the remaining 2,535
(65.4%) were spiked-in at the same concentration in both conditions (known negatives).
(Percentages do not add up to 100% because of a very small number of probe sets with
weak matching to multiple clones [Choe et al., 2005].)
In addition to the normalization methods used above, we included Cyclic Loess normal-
ization [Yang et al., 2002; Ballman et al., 2004] in this case, because it facilitates a better
comparison of results with previous studies [Choe et al., 2005; Schuster et al., 2007; Pear-
son, 2008; Calza et al., 2008; Ni et al., 2008; Zhu et al., 2010; Cheng et al., 2016]. Figure 8
summarizes the results obtained for the Golden Spike dataset, by displaying Receiver Op-
erating Characteristic (ROC) curves for the detection of differential gene expression. The
upper panel shows the true positive rate (as before, ratio between true positives and
treatment positives) versus the false positive rate (ratio between false positives and treat-
ment negatives), while the lower panel shows the number of true positives versus the
number of false positives. In both cases, detected and treatment positives/negatives were
restricted to known genes, following previous studies [Gaile and Miecznikowski, 2007;
Schuster et al., 2007; Pearson, 2008]. Doing otherwise would have given an excessively
dominant role to the issue of cross-hybridization in the analysis of differential gene expres-
sion [Schuster et al., 2007]. Additionally, the analysis was performed using only probe sets
with hybridization signal in all samples, with the aim of factoring out differences between
normalization methods caused by the response to missing data. Results obtained without
this restriction (Supplementary Fig. S3) or with t-tests instead of limma [Ritchie et al.,
2015] analysis (Supplementary Fig. S4) were very similar to those of Fig. 8.
The comparison of ROC curves shown in Fig. 8 highlight the superior performance of
MedianCD and, in particular, SVCD normalization. Dashed lines show results when
the list of known negatives was given as an input to some of the normalization methods
(something than cannot be done in real assays). It is remarkable that SVCD normalization
featured equally well with or without this information.
Points in Fig. 8 indicate the results when controlling the false discovery rate (FDR) to be
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below 0.01 (left point on each curve) or 0.05 (right point). Figure 8b shows reference lines
for actual FDR equal to 0.01, 0.05, 0.1, 0.2 and 0.5 (from left to right). In all cases, the
FDR was not adequately controlled, although the difference between intended and actual
FDR was notably smaller with MedianCD and SVCD normalization. Lack of control of
the FDR in the analysis of this dataset has been previously reported [Choe et al., 2005;
Pearson, 2008]. It is caused by the non-uniform (hence anomalous) distribution of p-values
for negative genes, which results from the analysis of differential gene expression [Dabney
and Storey, 2006; Gaile and Miecznikowski, 2007; Fodor et al., 2007; Pearson, 2008]. It has
been argued that this anomalous distribution of p-values is, in turn, a consequence of the
own experimental design of the dataset, in particular the lack of biological replication and
the way clone aliquots were mixed to produce each gene group with a given fold change
[Dabney and Storey, 2006]. Later studies have attributed this issue mostly to non-linear
or intensity-dependent effects, not properly corrected in the within-sample normalization
step (e.g. background correction) of the analysis pipeline [Gaile and Miecznikowski, 2007;
Fodor et al., 2007; Pearson, 2008; Zhu et al., 2010].
Concerning the identification of no-variation genes, both MedianCD and SVCD normal-
ization worked correctly. MedianCD normalization identified 561 no-variation genes, of
which 93.9% were known, and among which 84.1% were known negatives. SVCD normal-
ization, in comparison, featured better detection, with 1,224 no-variation genes identified,
of which 94.4% were known, and among which 90.0% were known negatives.
The design of the Platinum Spike dataset [Zhu et al., 2010] took into account the concerns
raised by the Golden Spike dataset, offering a dataset with two experimental conditions
and nine (three biological × three technical) replicates per condition, and including near
50% more spike-ins. Besides, differential gene expression was balanced, with respect
to both total mRNA amount and extent of over- and under-expression. Gene expres-
sion data was obtained with Affymetrix Drosophila Genome 2.0 microarrays. Excluding
Affymetrix internal control probes, the dataset contained a total of 18,769 probe sets, of
which 5,587 were spiked-in, called known as above. Among these, 1,940 (34.7%) were dif-
ferentially expressed (known positives) to varying degrees between 1.2- and 4-fold (1,057
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over-expressed, 883 under-expressed), while the remaining 3,406 (61.0%) were spiked-in
at the same concentration in both conditions (known negatives).
Figure 9 shows ROC curves for the Platinum Spike dataset. As above, only known genes
were considered for detected and treatment positives/negatives. Additionally, gene probes
were restricted to those with signal in all samples. Results obtained without this restric-
tion (Supplementary Fig. S5) or with t-tests instead of limma analysis (Supplementary
Fig. S6) were again very similar. In contrast to the Golden Spike dataset (Fig. 8), the
performance concerning true and false positives resulting from the different normalization
methods was much more comparable. In this case, MedianCD and SVCD normalization
were only marginally better. Note, however, that the FDR was again not properly con-
trolled (Fig. 9b). Similarly to the Golden Spike dataset, and despite biological replication
and a different experimental setup, obtained distributions of p-values for negative genes
have been reported to be non-uniform [Zhu et al., 2010]. This fact is consistent with
previous arguments relating the lack of control of the FDR to a general problem concern-
ing the correction of non-linearities in the preprocessing of microarray data [Gaile and
Miecznikowski, 2007; Fodor et al., 2007; Pearson, 2008; Zhu et al., 2010].
Regarding the identification of no-variation genes, MedianCD and SVCD normalization
also worked correctly with this dataset. MedianCD normalization identified 2,090 no-
variation genes, of which 95.4% were known, and among which 98.7% were known nega-
tives. SVCD normalization featured slightly better, with 2,232 no-variation genes identi-
fied, of which 95.3% were known, and among which 98.3% were known negatives.
Discussion
The lack-of-variation assumption underlying current methods of normalization was self-
fulfilling, removing variation in gene expression that was actually present. Moreover, it
had negative consequences for downstream analyses, as it removed potentially important
biological information and introduced errors in the detection of gene expression. The
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resulting decrease in statistical power or sensitivity is a handicap, which can be addressed
by increasing the number of samples per experimental condition. However, degradation
of the (already weak) control of the false discovery rate when using Median or Quantile
normalization is a major issue for real-world applications.
The removal of variation can be understood as additive errors in the estimation of nor-
malization factors. Considering data and errors vectorially (see Methods), the length of
each vector equals, after centering and up to a constant factor, the standard deviation of
the data or error. Errors of small magnitude, compared to the data variance, would only
have minor effects. However, errors of similar or greater magnitude than the data variance
may, depending on the vector lengths and the angle between the vectors, severely distort
the observed data variance. This will, in turn, cause spurious results in the statistical
analyses. Furthermore, the angles between the data and the correct normalization factors
(considered as vectors) are random, given that expression data reflect biological variation
while normalization factors respond to technical variation. If the assay is repeated, even
with exactly the same experimental setup, the errors in the normalization factors will vary
randomly, causing random spurious results in the downstream analyses. This explains, at
least partially, the lack of reproducibility found in transcriptomics studies, especially for
the detection of changes in gene expression of small-to-medium magnitude (up to 2-fold),
because variation of this size is more likely to be distorted by errors in the estimation
of normalization factors. Accordingly, the largest differences in numbers of differentially
expressed genes detected by Median and Quantile normalization, compared to MedianCD
and SVCD normalization, occurred in the treatments with the smallest magnitudes of
gene expression changes (Figs. 3a, 4).
The variation between medians displayed in Fig. 1j,k,m,n may seem surprising, given
routine expectations based on current methods (Fig. 1d,e,g,h). Nevertheless, this variation
inevitably results from the unbalance between over- and under-expressed genes. As an
illustration of this issue, let us consider a case with two experimental conditions, in which
the average expression of a given gene is less than the distribution median under one
condition, but greater than the median under the other. The variation of this gene alone
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will change the value of the median to the expression level of the next ranked gene.
Therefore, if the number of over-expressed genes is different from the number of under-
expressed genes, and enough changes cross the median boundary, then the median will
substantially differ between conditions. Only when differential expression is negligible or
is balanced with the respect to the median, will the median stay the same. Note that this
is a related but different requirement from the number of over- and under-expressed genes
being the same. This argument applies equally to any other quantile in the distribution
of gene expression. The case of Quantile normalization is the least favorable, because
it requires that changes of gene expression are balanced with respect to all distribution
quantiles.
Compared with other normalization approaches that try to identify no-variation genes
from expression data, such as Cross-Correlation [Chua et al., 2006], LVS [Calza et al.,
2008], or NVAS [Ni et al., 2008] normalization, our proposal is able to work correctly with
higher degrees of variation in gene expression, given that those methods are not expected
to work correctly when more than 50–60% of genes vary. The reason for this difference in
performance lies in that those methods use a binning strategy over the average expression
between conditions (Cross-Correlation, NVAS), or need to assume an a priori fraction
(usually 40-60%) of non-differentially expressed genes (LVS). When the majority of genes
are differentially expressed, very few of those bins may be suitable for normalization, or
the assumed fraction of non-differentially expressed genes may not hold. In contrast, our
approach makes one single search in a space of p-values, and without assuming any fraction
of non-differentially expressed genes. As long as there are a sufficient number of non-
differentially expressed genes, of the order of several hundreds, normalization is possible,
including cases with global mRNA changes or transcriptional amplification [van de Peppel
et al., 2003; Hannah et al., 2005, 2008; Love´n et al., 2012]. In general, it is a matter
of comparison between the magnitude of the error in the estimation of normalization
factors and the amount of biological variation. The estimation error decreases with the
number of no-variation genes detected (Fig. 2), and whenever normalization error is well
below biological variation, normalization between samples will be correct and beneficial
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for downstream analyses.
Our approach to normalization is based in four key ideas: first, decomposing the nor-
malization by experimental conditions and normalizing separately each condition before
normalizing the condition means; second, using the novel Standard-Vector normaliza-
tion (or alternatively median scaling) to perform each normalization; third, identifying
no-variation genes from the distribution of p-values resulting from a statistical test of
variation between conditions; and fourth, employing only no-variation genes for the final
between-condition normalization. These four ideas are grounded on rigorous mathemat-
ical statistics (see Methods and Supplementary Information). It is also worth noting
that both Median and Standard-Vector normalization, as methods for each normalization
step, are distribution-free methods; they do not assume Gaussianity or any other kind
of probability distribution for the expression levels of genes. MedianCD and SVCD nor-
malization are freely available in the R package cdnormbio, installable from GitHub (see
Code Availability).
Previous assumptions that gene variation is rather limited could suggest that there is no
need for more comprehensive normalization methods such as our proposal. In line with
this, it could be argued that the amount of variation in our real (E. crypticus) dataset
is exceptional and much larger than the variation likely to be occur in most experiments.
We think that this an invalid belief. Most of the available evidence concerning widespread
variation in gene expression is inadequate, because it involves circular reasoning. We have
shown here that current normalization methods, used by almost all studies to date, as-
sume no variation in gene expression between experimental conditions, and they remove
it if it exists, unless it is balanced. Therefore, these methods cannot be used to discern
the extent and balance of global variation in gene expression. Only methods that are
able to normalize correctly, whatever these extent and balance are, can be trusted for this
task. The fact that our methods perform well with large and unbalanced differential gene
expression does not imply that they perform poorly when differential gene expression is
more moderate or balanced. Our results show that this is not case. In the design of our
methods, no compromise was made to achieve good performance with high variation in
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exchange for not so good performance with low variation. The downside of our approach
lies elsewhere, in a greater algorithmic complexity and a greater demand of computing re-
sources. Yet, we consider this a minor demand, given the capabilities of today’s computers
and the resources required by current high-throughput assays.
Our results have being obtained from microarray data, but similar effects are expected
to be found in RNA-Seq assays. Current normalization procedures for RNA-Seq, such
as RPKM [Mortazavi et al., 2008], TMM [Robinson and Oshlack, 2010], or DESeq [An-
ders and Huber, 2010], perform between-sample normalization based on some form of
global scaling and under the assumption that most genes are not differentially expressed.
This makes RPKM, TMM, and DESeq normalization, in what concerns between-sample
normalization and the removal or distortion of variation discussed here, similar to conven-
tional Median normalization. An example of this issue, including results from microarray
and RNA-Seq assays, has been reported in a study of the transcriptional amplification
mediated by the oncogene c-Myc [Love´n et al., 2012].
Importantly, MedianCD and SVCD normalization were designed with no dependencies
on any particular aspect of the technology used to globally measure gene expression, i.e.
microarrays or RNA-Seq. The numbers in the input data are interpreted as steady state
concentrations of mRNA molecules, in order to identify the normalization factors, and
irrespectively of whether the concentrations were obtained from fluorescence intensities
of hybridized cDNA (microarrays) or from counts of fragments of cDNA (RNA-Seq).
Both technologies require between-sample normalization, because in some step of the
assay the total mRNA or cDNA mass in each sample must be equalized within a given
range required by the experimental platform, This equalization of total mass, together
with other sources of variation in the total efficiency of the assay, amounts to a factor
multiplying the concentration of each mRNA species. This factor is different for each
sample, and it is what between-sample normalization aims to detect and correct for.
Moreover, the total mRNA mass in each sample is, in many cases, mostly determined
by a few highly expressed genes, rather than an unbiased average over the total mRNA
population. This makes between-sample normalization critical regarding comparisons of
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gene expression between different experimental conditions, as our results illustrate. It is
also important to highlight that this between-sample uncertainty in the measurement of
mRNA concentrations is different from other issues, such as for example non-linearities.
These other problems are usually more specific to each technology, and they are the
scope of within-sample normalization (e.g. background correction for microarrays and
gene-length normalization for RNA-Seq), which are obviously also necessary and should
be applied before between-sample normalization. Similarly, methods that address the
influence of biological or technical confounding factors on downstream analyses, such
as SVA [Leek and Storey, 2007] or PEER [Stegle et al., 2010], should be applied when
necessary, after normalizing.
Finally, the significance of widespread variation in gene expression merits consideration
from the viewpoint of molecular and cell biology. Established understanding about the
regulation of gene expression considers it as a set of processes that generally switch on
or off the expression of genes, performed mostly at transcription initiation, by the com-
binatorial regulation of a large number of transcription factors, and with an emphasis on
gene expression programs associated with cell differentiation and development. Recent
studies, however, have expanded this understanding, offering a more complex perspective
on the regulation of gene expression, by identifying other rate-limiting regulation points
between transcription initiation and protein translation, such as transcription elongation
and termination, as well as mRNA processing, transport and degradation. Promoter-
proximal pausing of RNA polymerase II (in eukaryotes) [Core et al., 2008; Adelman and
Lis, 2012] and transcript elongation [Jonkers and Lis, 2015], in particular, have received
a great deal of attention recently, in connection with gene products involved in signal
transduction pathways. These mechanisms, which seem to be highly conserved among
metazoans, would allow cells to tune the expression of activated genes in response to sig-
nals concerning, for example, homeostasis, environmental stress or immune response. As
an illustration, studies about the transcription amplification mediated by the oncogene c-
Myc have uncovered that it regulates the promoter-proximal pausing of RNA polymerase
II, affecting a large number of genes already activated by other regulatory mechanisms
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[Lin et al., 2012; Nie et al., 2012; Littlewood et al., 2012]. Our results for the toxicity
experiment with E. crypticus are consistent with regulatory capabilities for broad fine-
tuning of gene expression levels, far beyond what conventional methods of normalization
would allow to detect. This contrast underlines that normalization methods that truly
preserve variation between experimental conditions are necessary for high-throughput as-
says exploring genome-wide regulation of gene expression, as required by current research
in molecular and cell biology.
In summary, this study proves that large numbers of genes can change in expression level
across experimental conditions, and too extensively to ignore in the normalization of gene
expression data. Current normalization methods for gene expression microarrays and
RNA-Seq, because of a lack-of-variation assumption, likely remove and distort variation
in gene expression. The normalization methods proposed here solve this problem, offering
a means to investigate broad changes in gene expression that have remained hidden to
date. We expect this to provide revealing insights about diverse biomolecular processes,
particularly those involving substantial numbers of genes, and to assist efforts to realize
the full potential of gene expression profiling.
Methods
Test Organism and Exposure Media
The test species was Enchytraeus crypticus. Individuals were cultured in Petri dishes
containing agar medium, in controlled conditions [Gomes et al., 2015b].
For copper (Cu) exposure, a natural soil collected at Hygum, Jutland, Denmark was
used [Gomes et al., 2015b; Scott-Fordsmand et al., 2000]. For silver (Ag) and nickel (Ni)
exposure, the natural standard soil LUFA 2.2 (LUFA Speyer, Germany) was used [Gomes
et al., 2015b]. The exposure to ultra-violet (UV) radiation was done in ISO reconstituted
water [OECD, 2004a].
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Test Chemicals
The tested Cu forms [Gomes et al., 2015b] included copper nitrate (Cu(NO3)2 ·3H2O >
99%, Sigma Aldrich), Cu nanoparticles (Cu-NPs, 20–30 nm, American Elements) and Cu
nanowires (Cu-Nwires, as synthesized [Chang et al., 2005]).
The tested Ag forms [Gomes et al., 2015b] included silver nitratre (AgNO3 > 99%, Sigma
Aldrich), non-coated Ag nanoparticles (Ag-NPs Non-Coated, 20–30 nm, American Ele-
ments), Polyvinylpyrrolidone (PVP)-coated Ag nanoparticles (Ag-NPs PVP-Coated, 20–
30 nm, American Elements), and Ag NM300K nanoparticles (Ag NM300K, 15 nm, JRC
Repository). The Ag NM300K was dispersed in 4% Polyoxyethylene Glycerol Triolaete
and Polyoxyethylene (20) orbitan mono-Laurat (Tween 20), thus the dispersant was tested
alone as control (CTdisp).
The tested Ni forms included nickel nitrate (Ni(NO3)2 ·6H2O ≥ 98.5%, Fluka) and Ni
nanoparticles (Ni-NPs, 20 nm, American Elements).
Spiking Procedure
Spiking for the Cu and Ag materials was done as previously described [Gomes et al.,
2015b]. For the Ni materials, the Ni-NPs were added to the soil as powder, following
the same procedure as for the Cu materials. NiNO3, being soluble, was added to the
pre-moistened soil as aqueous dispersions.
The concentrations tested were selected based on the reproduction effect concentrations
EC20 and EC50, for E. crypticus, within 95% of confidence intervals, being: CuNO3
EC20/50 = 290/360 mgCu/kg, Cu-NPs EC20/50 = 980/1760 mgCu/kg, Cu-Nwires EC20/50
= 850/1610 mgCu/kg, Cu-Field EC20/50 = 500/1400 mgCu/kg, AgNO3 EC20/50 = 45/60
mgAg/kg, Ag-NP PVP-coated EC20/50 = 380/550 mgAg/kg, Ag-NP Non-coated EC20/50
= 380/430 mgAg/kg, Ag NM300K EC20/50 = 60/170 mgAg/kg, CTdisp = 4% w/w Tween
20, NiNO3 EC20/50 = 40/60 mgNi/kg, Ni-NPs EC20/50 = 980/1760 mgNi/kg.
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Four biological replicates were performed per test condition, including controls. For Cu
exposure, the control condition for all the treatments consisted of soil from a control area
at Hygum site, which has a Cu background concentration of 15 mg/kg [Scott-Fordsmand
et al., 2000]. For Ag exposure, two control sets were performed: CT (un-spiked LUFA soil,
to be the control condition for AgNO3, Ag-NPs PVP-Coated and Ag-NPs Non-Coated
treatments) and CTdisp (LUFA soil spiked with the dispersant Tween 20, to be the
control condition for the Ag NM300K treatments). For Ni exposure, the control consisted
of un-spiked LUFA soil.
Exposure Details
In soil (i.e. for Cu, Ag and Ni) exposure followed the standard ERT [OECD, 2004b]
with adaptations as follows: twenty adults with well-developed clitellum were introduced
in each test vessel, containing 20 g of moist soil (control or spiked). The organisms
were exposed for three and seven days under controlled conditions of photoperiod (16:8
h light:dark) and temperature 20 ± 1 ◦C without food. After the exposure period, the
organisms were carefully removed from the soil, rinsed in deionized water and frozen in
liquid nitrogen. The samples were stored at −80 ◦C, until analysis.
For UV exposure, the test conditions [OECD, 2004a] were adapted for E. crypticus [Gomes
et al., 2015a]. The exposure was performed in 24-well plates, where each well corresponded
to a replicate and contained 1 ml of ISO water and five adult organisms with clitellum.
The test duration was five days, at 20±1 ◦C. The organisms were exposed to UV on a daily
basis, during 15 minutes per day to two UV intensities (280–400nm) of 1669.25 ± 50.83
and 1804.08 ± 43.10 mW/m2, corresponding to total UV doses of 7511.6 and 8118.35
J/m2, respectively. The remaining time was spent under standard laboratory illumination
(16:8 h photoperiod). UV radiation was provided by an UV lamp (Spectroline XX15F/B,
Spectronics Corporation, NY, USA, peak emission at 312 nm) and a cellulose acetate sheet
was coupled to the lamp to cut-off UVC-range wavelengths [Gomes et al., 2015a]. Thirty
two replicates per test condition (including control without UV radiation) were performed
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to obtain 4 biological replicates for RNA extraction, each one with 40 organisms. After
the exposure period, the organisms were carefully removed from the water and frozen in
liquid nitrogen. The samples were stored at −80 ◦C, until analysis.
RNA Extraction, Labeling and Hybridization
RNA was extracted from each replicate, which contained a pool of 20 and 40 organisms,
for soil and water exposure, respectively. Three biological replicates per test treatment
(including controls) were used. Total RNA was extracted using SV Total RNA Isolation
System (Promega). The quantity and purity were measured spectrophotometrically with a
nanodrop (NanoDrop ND-1000 Spectrophotometer) and its quality checked by denaturing
formaldehyde agarose gel electrophoresis.
500 ng of total RNA were amplified and labeled with Agilent Low Input Quick Amp
Labeling Kit (Agilent Technologies, Palo Alto, CA, USA). Positive controls were added
with the Agilent one-color RNA Spike-In Kit. Purification of the amplified and labeled
cRNA was performed with RNeasy columns (Qiagen, Valencia, CA, USA).
The cRNA samples were hybridized on custom Gene Expression Agilent Microarrays (4
x 44k format), with a single-color design [Castro-Ferreira et al., 2014]. Hybridizations
were performed using the Agilent Gene Expression Hybridization Kit and each biological
replicate was individually hybridized on one array. The arrays were hybridized at 65 ◦C
with a rotation of 10 rpm, during 17 h. Afterwards, microarrays were washed using
Agilent Gene Expression Wash Buffer Kit and scanned with the Agilent DNA microarray
scanner G2505B.
Data Acquisition
Fluorescence intensity data was obtained with Agilent Feature Extraction Software v. 10.7.3.1,
using recommended protocol GE1 107 Sep09. Quality control was done by inspecting the
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reports on the Agilent Spike-in control probes.
Data Analysis
Analyses were performed with R [R Core Team, 2016] v. 3.3.1, using R packages plotrix
[Lemon, 2006] v. 3.6.3 and RColorBrewer [Neuwirth, 2014] v. 1.1.2, and with Bioconductor
[Huber et al., 2015] v. 3.3 packages affy [Gautier et al., 2004] v. 1.50.0, drosgenome1.db
v .3.2.3, drosophila2.db v. 3.2.3, genefilter v. 1.54.2, and limma [Ritchie et al., 2015]
v. 3.28.20. Background correction was carried out by Agilent Feature Extraction software
for the real (E. crypticus) dataset, while the Affymetrix MAS5 algorithm, as implemented
in the limma package, was used for the Golden and Platinum Spike datasets.
To ensure an optimal comparison between the different normalization methods, only gene
probes with good signal quality (flag IsPosAndSignif = True) in all samples were employed
for the analysis of the E. crypticus dataset. This implied the selection of 18,339 gene
probes from a total of 43,750. For the Golden and Platinum Spike datasets, data were
considered as missing when probe sets were not called present by the MAS5 algorithm.
The synthetic dataset without differential gene expression was generated gene by gene
as normal variates with mean and variance equal, respectively, to the sample mean and
sample variance of the expression levels for each gene, as detected from the real E. cryp-
ticus dataset after SVCD normalization. The synthetic dataset with differential gene
expression was generated equally, except for the introduction of differences in expression
averages between treatments and controls. The magnitude of the difference in averages
was equal, for each differentially expressed gene (DEG), to twice the sample variance.
The percentage of DEGs for each treatment was chosen randomly, in logarithmic scale,
from a range between 0.9% and 90%, while ensuring that 10% of genes were not differ-
entially expressed across the entire dataset. One third of the treatments were mostly
over-expressed (for each treatment independently, the probability of a DEG being over-
expressed was O ∼ 1 − |N (0, 0.12)|), one third of the treatments were mostly under-
expressed (O ∼ |N (0, 0.12)|), and the remaining third had mostly balanced differential
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gene expression (O ∼ N (0.5, 0.12)). For both synthetic datasets, the applied normal-
ization factors were those detected by SVCD normalization from the real E. crypticus
dataset.
Median normalization was performed, for each sample, by subtracting the median of
the distribution of expression levels, and then adding the overall median to preserve the
global expression level. Quantile normalization was performed as implemented in the
limma package.
The two condition-decomposition normalizations, MedianCD and SVCD, proceeded in
the same way: first, independent within-condition normalization for each experimental
condition, using all genes. Then, one between-condition normalization, iteratively iden-
tifying no-variation genes and normalizing until convergence of the set of no-variation
genes. And finally, another between-condition normalization using only the no-variation
genes detected, to calculate the between-condition normalization factors.
The criterion for convergence of MedianCD normalization was to require that the relative
changes in the standard deviation of the normalization factors were less than 0.1%, or less
than 10% for 10 steps in a row. In the case of SVCD normalization, convergence required
that numerical errors were, compared to estimated statistical errors (see below), less than
1%, or less than 10% for 10 steps in a row. Convergence of the set of no-variation genes was
achieved by intersection of the sets found during 10 additional steps under convergence
conditions. These default convergence parameters were used for all the MedianCD and
SVCD normalizations reported, with the exception of MedianCD with the Golden Spike
dataset, which used 30% (instead of 10%) of relative change for 10 steps in a row, to reach
convergence.
In SVCD normalization, the distribution of standard vectors was trimmed in each step to
remove the 1% more extreme values of variance.
Differentially expressed genes were identified with limma analysis or t-tests, controlling
the false discovery rate to be below 5%, independently for each comparison of treatment
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versus control.
The reference distributions with permutation symmetry shown in the polar plots of Sup-
plementary Movies S1–S3 were calculated through the six possible permutations of the
empirical standard vectors. The Watson U2 statistic was calculated with the two-sample
test [Durbin, 1973], comparing with an equal number of samples obtained by sampling
with replacement the permuted standard vectors.
Condition Decomposition of the Normalization Problem
In a gene expression dataset with g genes, c experimental conditions and n samples per
condition, the observed expression levels of gene j in condition k, y
(k)
j = (y
(k)
1j , . . . , y
(k)
nj )
′,
can be expressed in log2-scale as
y
(k)
j = x
(k)
j + a
(k), (1)
where x
(k)
j is the vector of true gene expression levels and a
(k) is the vector of normalization
factors.
Given a sample vector x, the mean vector is x = x¯1, and the residual vector is x˜ = x−x.
Then, (1) can be linearly decomposed into
y
(k)
j = x
(k)
j + a
(k), (2)
y˜
(k)
j = x˜
(k)
j + a˜
(k). (3)
Equations (3) define the within-condition normalizations for each condition k. The scalar
values in (2) are used to obtain the equations on condition means,
y∗j = x
∗
j + a
∗, (4)
y˜∗j = x˜
∗
j + a˜
∗. (5)
The between-condition normalization is defined by (5). Equations (4) reduce to a single
number, which is irrelevant to the normalization. The complete solution for each condition
is obtained with a(k) = a(k) + a˜(k).
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For full details about this condition-decomposition approach, see Supplementary Mathe-
matical Methods in the Supplementary Information.
Standard-Vector Normalization
The n samples of gene j in a given condition can be modeled with the random vectors
Xj,Yj ∈ Rn. Again, Yj = Xj + a, where a is a fixed vector of normalization factors.
It can be proved under fairly general assumptions (see Supplementary Information), that
the true standard vectors have zero expected value
E
(
√
n− 1 X˜j
‖X˜j‖
)
= 0, (6)
whereas the observed standard vectors verify, as long as a 6= 0,
0 < E
(
√
n− 1 Y˜j
‖Y˜j‖
)′
a˜
‖a˜‖ < E
(
√
n− 1 1
‖Y˜j‖
)
‖a˜‖. (7)
This motivates the following iterative procedure to solve (3) and (5) (standard-vector
normalization):
ŷ
(0)
j = y˜j, (8)
ŷ
(t)
j = ŷ
(t−1)
j − b̂(t−1), for t ≥ 1, (9)
b̂(t) =
g∑
j=1
ŷ
(t)
j
‖ŷ(t)j ‖
g∑
j=1
1
‖ŷ(t)j ‖
, for t ≥ 0. (10)
At convergence, limt→∞ b̂(t) = 0, which implies limt→∞ ŷ
(t)
j = x˜j and
∑∞
t=0 b̂
(t) = a˜.
Convergence is faster the more symmetric the empirical distribution of x˜j/‖x˜j‖ is on the
unit (n − 2)-sphere. Convergence is optimal with spherically symmetric distributions,
such as the Gaussian distribution, because in that case
E
(
Y˜j
‖Y˜j‖
)
= λa˜, with 0 < λ < E
(
1
‖Y˜j‖
)
. (11)
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Assuming no dependencies between genes, an approximation of the statistical error at
step t can be obtained with
E
(
‖b̂(t)‖
)
≈
√
g
g∑
j=1
1
‖ŷ(t)j ‖
. (12)
This statistical error was compared with the numerical error to assess convergence.
See Supplementary Mathematical Methods in the Supplementary Information for full
details about this algorithm. See also Supplementary Movies S1–S3 for normalization
examples.
Identification of No-Variation Genes
No-variation genes were identified with one-sided Kolmogorov-Smirnov tests, as goodness-
of-fit tests against the uniform distribution, carried out on a distribution of p-values.
These p-values were obtained from ANOVA tests on the expression levels of genes, grouped
by experimental condition. The KS test was rejected at α = 0.001.
See Supplementary Mathematical Methods in the Supplementary Information for more
details about this approach to identify no-variation genes. See also Supplementary Movies
S4–S6 for examples of use.
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Figure 1: MedianCD and SVCD normalization resulted in the detection of much larger
between-condition variation in the datasets with differential gene expression, compared
to Median and Quantile normalization. Panels show interquartile ranges of expression
levels for the 153 samples, grouped by the 51 experimental conditions (Ag, blue-yellow;
Cu, red-cyan; Ni, green-orange; UV, purple; see Supplementary Table S1). Black lines
indicate medians. Rows and columns correspond to normalization methods and datasets,
respectively, as labeled.
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Figure 2: The selection of genes for the final between-condition normalization in Me-
dianCD and SVCD normalization was crucial to preserve the variation between condi-
tions. Panels show the detected variation as a function of the number of genes used in
the between-condition normalization, for the real dataset (a), synthetic dataset with dif-
ferential gene expression (b), and synthetic dataset without differential gene expression
(c). Between-condition variation is represented as the standard deviation of the within-
condition mean averages (averages of sample means, for all samples of the condition). See
Supplementary Fig. S1 for results using within-condition median averages, with similar
behavior. Each point in each panel indicates the variation obtained with one complete
normalization (black circles, MedianCD normalization; blue circles, SVCD normaliza-
tion). Genes were selected in two ways: randomly (empty circles) or in decreasing order
of p-values from a test for detecting no-variation genes (filled circles). Big circles show
the working points corresponding to the results depicted in Fig. 1j–o, which were chosen
automatically. Black dashed lines show references for n−1/2 decays, with the same values
in all panels.
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Figure 3: MedianCD and SVCD normalization allowed to detect much larger numbers
of differentially expressed genes (DEGs) in the datasets with differential gene expres-
sion. Panels show results for the real dataset (a), synthetic dataset with differential gene
expression (b), and synthetic dataset without differential gene expression (c). They dis-
play the number of DEGs for each treatment compared to the corresponding control,
obtained after applying the four normalization methods (empty black circles, Median
normalization; empty red up triangles, Quantile normalization; filled green circles, Me-
dianCD normalization; filled blue up triangles, SVCD normalization). For the synthetic
dataset with differential gene expression (b), the numbers of treatment positives are also
shown, as empty black down triangles. In each panel, treatments are ordered according
to the number of DEGs identified with SVCD normalization, increasing from left to right
(see Supplementary Table 2, for real dataset). Differential gene expression was analyzed
with R/Bioconductor package limma. Supplementary Fig. S2 shows results obtained with
t-tests, qualitatively similar but with much lower detection of differential gene expression.
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Figure 4: For the real dataset, MedianCD and SVCD normalization allowed to de-
tect variation in gene expression of smaller magnitude than with Median and Quantile
normalization. Boxplots display absolute values of DEG fold changes, for each treatment
compared to the corresponding control, obtained after Median normalization (a), Quantile
normalization (b), MedianCD normalization (c), and SVCD normalization (d). Boxplots
are colored by treatment, with the same color code as in Figs. 1. All panels have the same
order of treatments as in Fig. 3a, i.e. in increasing number of DEGs identified with SVCD
normalization (Supplementary Table 2). Dashed horizontal lines indicate references of
1.5-fold and 2-fold changes.
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Figure 5: For the real dataset, detected differential gene expression was unbalanced,
specially after using MedianCD and SVCD normalization and for the treatments with
more DEGs (Fig. 3a). Panels show the balance of differential gene expression, for each
treatment compared to the corresponding control, obtained after Median normalization
(a), Quantile normalization (b), MedianCD normalization (c), and SVCD normalization
(d). Each point represents the balance of differential gene expression, B (B = 0, same
number of over- and under-expressed genes; B = +1, all DEGs over-expressed; B = −0.5,
75% DEGs under-expressed). Points are colored by treatment, with the same color code as
in Figs. 1, 4. All panels have the same order of treatments as in Figs. 3a, 4, i.e. in increasing
number of DEGs identified with SVCD normalization (Supplementary Table 2). Dashed
horizontal lines indicate references for balanced differential gene expression (B = 0).
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Figure 6: In the synthetic dataset with differential gene expression, and with more
than 10% of treatment positives (Fig. 3b), Median and Quantile normalization resulted
in less statistical power and uncontrolled false discovery rate. The panels display the true
positive rate (a) and false discovery rate (b), for each treatment compared to the corre-
sponding control, obtained after applying the four normalization methods (same symbols
as in Fig. 3; empty black circles, Median normalization; empty red up triangles, Quan-
tile normalization; filled green circles, MedianCD normalization; filled blue up triangles,
SVCD normalization). Both panels have the same order of treatments as in Fig. 3b, i.e.
in increasing number of differentially expressed genes identified with SVCD normaliza-
tion. Differential gene expression was analyzed with R/Bioconductor package limma. The
dashed horizontal line in (b) indicates the desired bound on the false discovery rate at
0.05.
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Figure 7: In the synthetic dataset with differential gene expression (Fig. 6), the un-
balance between over- and under-expressed genes was a key factor in the lowered true
positive rate and uncontrolled false discovery rate obtained after Median and Quantile
normalization. Panels show the true positive rate (a) and false discovery rate (b) as a
function of the balance of differential gene expression, B (B = 0, same number of over-
and under-expressed genes; B = +1, all DEGs over-expressed; B = −0.5, 75% DEGs
under-expressed). Each point in both panels represents the results for one treatment
compared to the corresponding control, obtained after applying the four normalization
methods (same symbols as in Figs. 3, 6; empty black circles, Median normalization; empty
red up triangles, Quantile normalization; filled green circles, MedianCD normalization;
filled blue up triangles, SVCD normalization). Differential gene expression was analyzed
with R/Bioconductor package limma. The dashed horizontal line in (b) indicates the
desired bound on the false discovery rate at 0.05.
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Figure 8: In the Golden Spike dataset, the best detection of differential gene expression
was achieved after using MedianCD and, specially, SVCD normalization. Panels display
ROC curves, with the true positive rate versus the false positive rate (a), or the number
of true positives versus the number of false positives (b). Each curve shows the results
obtained after applying the four normalization methods plus Cyclic Loess normalization
(same colors and symbols as in Figs. 3, 6, 7; black curve with empty black circles, Median
normalization; red curve with empty red up triangles, Quantile normalization; green
curve with filled green circles, MedianCD normalization; blue curve with filled blue up
triangles, SVCD normalization; magenta curve with filled magenta diamonds, Cyclic Loess
normalization). Dashed curves with lightly filled symbols, overlapping the response of
SVCD normalization, show results when the list of known negatives was provided to
MedianCD, SVCD, and Cyclic Loess normalization. The two points per normalization
method show results when controlling the false discovery rate (FDR) to be below 0.01
(left point) or 0.05 (right point). Dashed lines in (b) show references for actual FDR
equal to 0.01, 0.05, 0.1, 0.2, or 0.5 (from left to right). Compared to MedianCD and
SVCD normalization, the other normalization methods resulted in notably more severe
degradation of the FDR.
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Figure 9: In the Platinum Spike dataset, all normalization methods resulted in similar
detection of differential gene expression, with MedianCD and SVCD normalization being
only marginally better. Panels display ROC curves, with the true positive rate versus the
false positive rate (a), or the number of true positives versus the number of false positives
(b). Each curve shows the results obtained after applying the four normalization methods
plus Cyclic Loess normalization (same colors and symbols as in Figs. 3, 6–8; black curve
with empty black circles, Median normalization; red curve with empty red up triangles,
Quantile normalization; green curve with filled green circles, MedianCD normalization;
blue curve with filled blue up triangles, SVCD normalization; magenta curve with filled
magenta diamonds, Cyclic Loess normalization). Dashed curves with lightly filled symbols
show results when the list of known negatives was provided to MedianCD, SVCD, and
Cyclic Loess normalization. As in Fig. 8, the two points per normalization method show
results when controlling the false discovery rate (FDR) to be below 0.01 (left point) or
0.05 (right point). Dashed lines in (b) show references for actual FDR equal to 0.01, 0.05,
0.1, 0.2, or 0.5 (from left to right). Compared to the Golden Spike dataset (Fig. 8), the
difference between normalization methods in the resulting degradation of the FDR was
smaller for this dataset.
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Supplementary Tables
Supplementary Table S1: Experimental conditions of the toxicity experiment on E.
crypticus, listed in the same order as they appear in each panel of Fig. 1, from left to
right.
Condition ID Condition description
1 Ag.AgNO3.EC20.3d AgNO3 EC20 3 days
2 Ag.AgNO3.EC20.7d AgNO3 EC20 7 days
3 Ag.AgNO3.EC50.3d AgNO3 EC50 3 days
4 Ag.AgNO3.EC50.7d AgNO3 EC50 7 days
5 Ag.Coated.EC20.3d Ag-NPs PVP-Coated EC20 3 days
6 Ag.Coated.EC20.7d Ag-NPs PVP-Coated EC20 7 days
7 Ag.Coated.EC50.3d Ag-NPs PVP-Coated EC50 3 days
8 Ag.Coated.EC50.7d Ag-NPs PVP-Coated EC50 7 days
9 Ag.NC.EC20.3d Ag-NPs Non-Coated EC20 3 days
10 Ag.NC.EC20.7d Ag-NPs Non-Coated EC20 7 days
11 Ag.NC.EC50.3d Ag-NPs Non-Coated EC50 3 days
12 Ag.NC.EC50.7d Ag-NPs Non-Coated EC50 7 days
13 Ag.NM300K.EC20.3d Ag NM300K EC20 3 days
14 Ag.NM300K.EC20.7d Ag NM300K EC20 7 days
15 Ag.NM300K.EC50.3d Ag NM300K EC50 3 days
16 Ag.NM300K.EC50.7d Ag NM300K EC50 7 days
17 Ag.CT.3d Ag Control 3 days
18 Ag.CT.7d Ag Control 7 days
19 Ag.CTD.3d Ag Control Dispersant 3 days
20 Ag.CTD.7d Ag Control Dispersant 7 days
21 Cu.CuNO3.EC20.3d CuNO3 EC20 3 days
22 Cu.CuNO3.EC20.7d CuNO3 EC20 7 days
23 Cu.CuNO3.EC50.3d CuNO3 EC50 3 days
24 Cu.CuNO3.EC50.7d CuNO3 EC50 7 days
25 Cu.Cu.NPs.EC20.3d Cu-NPs EC20 3 days
26 Cu.Cu.NPs.EC20.7d Cu-NPs EC20 7 days
27 Cu.Cu.NPs.EC50.3d Cu-NPs EC50 3 days
28 Cu.Cu.NPs.EC50.7d Cu-NPs EC50 7 days
29 Cu.Cu.Nwires.EC20.3d Cu-NWires EC20 3 days
30 Cu.Cu.Nwires.EC20.7d Cu-NWires EC20 7 days
31 Cu.Cu.Nwires.EC50.3d Cu-NWires EC50 3 days
32 Cu.Cu.Nwires.EC50.7d Cu-NWires EC50 7 days
33 Cu.Cu.field.EC20.3d Cu-Field EC20 3 days
34 Cu.Cu.field.EC20.7d Cu-Field EC20 7 days
35 Cu.Cu.field.EC50.3d Cu-Field EC50 3 days
36 Cu.Cu.field.EC50.7d Cu-Field EC50 7 days
37 Cu.CT.3d Cu Control 3 days
38 Cu.CT.7d Cu Control 7 days
39 Ni.NiNO3.EC20.3d NiNO3 EC20 3 days
40 Ni.NiNO3.EC20.7d NiNO3 EC20 7 days
41 Ni.NiNO3.EC50.3d NiNO3 EC50 3 days
42 Ni.NiNO3.EC50.7d NiNO3 EC50 7 days
43 Ni.Ni.NPs.EC20.3d Ni-NPs EC20 3 days
44 Ni.Ni.NPs.EC20.7d Ni-NPs EC20 7 days
45 Ni.Ni.NPs.EC50.3d Ni-NPs EC50 3 days
46 Ni.Ni.NPs.EC50.7d Ni-NPs EC50 7 days
47 Ni.CT.3d Ni Control 3 days
48 Ni.CT.7d Ni Control 7 days
49 Uv.UV.D1.5d UV Dose 1
50 Uv.UV.D2.5d UV Dose 2
51 Uv.CT.5d UV Control
Condition
number
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Supplementary Table S2: Treatment vs control comparisons, listed in increasing number
of differentially expressed genes (DEGs), obtained for the real E. crypticus dataset with
SVCD normalization and limma analysis. This is the same order as in Figs. 3a, 4, 5, from
left to right.
Treatment ID Control ID Treatment description
1 Ag.NM300K.EC20.7d Ag.CTD.7d Ag NM300K EC20 7 days 2
2 Ni.Ni.NPs.EC20.7d Ni.CT.7d Ni-NPs EC20 7 days 7
3 Cu.CuNO3.EC50.7d Cu.CT.7d CuNO3 EC50 7 days 26
4 Cu.CuNO3.EC20.3d Cu.CT.3d CuNO3 EC20 3 days 27
5 Cu.Cu.NPs.EC20.3d Cu.CT.3d Cu-NPs EC20 3 days 31
6 Ag.AgNO3.EC50.7d Ag.CT.7d AgNO3 EC50 7 days 33
7 Cu.Cu.NPs.EC20.7d Cu.CT.7d Cu-NPs EC20 7 days 33
8 Ag.NM300K.EC20.3d Ag.CTD.3d Ag NM300K EC20 3 days 38
9 Ag.NM300K.EC50.3d Ag.CTD.3d Ag NM300K EC50 3 days 52
10 Ni.NiNO3.EC20.3d Ni.CT.3d NiNO3 EC20 3 days 74
11 Ni.NiNO3.EC20.7d Ni.CT.7d NiNO3 EC20 7 days 79
12 Ag.NC.EC20.7d Ag.CT.7d Ag-NPs Non-Coated EC20 7 days 106
13 Ni.Ni.NPs.EC50.7d Ni.CT.7d Ni-NPs EC50 7 days 107
14 Ag.AgNO3.EC20.7d Ag.CT.7d AgNO3 EC20 7 days 113
15 Ag.NC.EC50.7d Ag.CT.7d Ag-NPs Non-Coated EC50 7 days 163
16 Ag.NC.EC20.3d Ag.CT.3d Ag-NPs Non-Coated EC20 3 days 240
17 Ag.AgNO3.EC50.3d Ag.CT.3d AgNO3 EC50 3 days 260
18 Ag.Coated.EC20.7d Ag.CT.7d Ag-NPs PVP-Coated EC20 7 days 261
19 Ni.NiNO3.EC50.7d Ni.CT.7d NiNO3 EC50 7 days 329
20 Cu.Cu.NPs.EC50.7d Cu.CT.7d Cu-NPs EC50 7 days 343
21 Ag.Coated.EC50.7d Ag.CT.7d Ag-NPs PVP-Coated EC50 7 days 346
22 Cu.Cu.Nwires.EC50.7d Cu.CT.7d Cu-NWires EC50 7 days 383
23 Cu.CuNO3.EC20.7d Cu.CT.7d CuNO3 EC20 7 days 393
24 Cu.Cu.Nwires.EC20.7d Cu.CT.7d Cu-NWires EC20 7 days 479
25 Cu.CuNO3.EC50.3d Cu.CT.3d CuNO3 EC50 3 days 522
26 Ag.AgNO3.EC20.3d Ag.CT.3d AgNO3 EC20 3 days 908
27 Ag.Coated.EC20.3d Ag.CT.3d Ag-NPs PVP-Coated EC20 3 days 937
28 Ag.NM300K.EC50.7d Ag.CTD.7d Ag NM300K EC50 7 days 1,264
29 Ni.Ni.NPs.EC20.3d Ni.CT.3d Ni-NPs EC20 3 days 1,464
30 Cu.Cu.field.EC20.7d Cu.CT.7d Cu-Field EC20 7 days 1,627
31 Ni.NiNO3.EC50.3d Ni.CT.3d NiNO3 EC50 3 days 1,647
32 Uv.UV.D2.5d Uv.CT.5d UV Dose 2 1,864
33 Ni.Ni.NPs.EC50.3d Ni.CT.3d Ni-NPs EC50 3 days 2,334
34 Cu.Cu.field.EC50.3d Cu.CT.3d Cu-Field EC50 3 days 3,570
35 Cu.Cu.field.EC50.7d Cu.CT.7d Cu-Field EC50 7 days 4,396
36 Uv.UV.D1.5d Uv.CT.5d UV Dose 1 4,745
37 Cu.Cu.NPs.EC50.3d Cu.CT.3d Cu-NPs EC50 3 days 5,988
38 Cu.Cu.field.EC20.3d Cu.CT.3d Cu-Field EC20 3 days 9,225
39 Ag.Coated.EC50.3d Ag.CT.3d Ag-NPs PVP-Coated EC50 3 days 9,478
40 Cu.Cu.Nwires.EC20.3d Cu.CT.3d Cu-NWires EC20 3 days 9,751
41 Ag.NC.EC50.3d Ag.CT.3d Ag-NPs Non-Coated EC50 3 days 9,884
42 Cu.Cu.Nwires.EC50.3d Cu.CT.3d Cu-NWires EC50 3 days 10,285
Comparison 
number
Number of 
DEGs
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Supplementary Figure S1: Representing between-condition variation as the standard
deviation of the within-condition median averages (averages of sample medians, for all
samples of the condition) produced similar results to those obtained with within-condition
mean averages (Fig. 2). Panels show detected variation as a function of the number of
genes used in the between-condition normalization, for the real dataset (a), synthetic
dataset with differential gene expression (b), and synthetic dataset without differential
gene expression (c). Labeling is the same as in Fig. 2. Each point in each panel indicates
the variation obtained with one complete normalization (black circles, MedianCD normal-
ization; blue circles, SVCD normalization). Gene were selected in two ways: randomly
(empty circles) or in decreasing order of p-values from a test for detecting no-variation
genes (filled circles). Big circles show the working points corresponding to the results
depicted in Fig. 1j–o. Black dashed lines show references for n−1/2 decays, with the same
values in all panels.
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Supplementary Figure S2: With t-tests instead of limma analysis (Fig. 3a), MedianCD
and SVCD normalization also allowed to detect larger numbers of differentially expressed
genes (DEGs), compared to Median and Quantile normalization. Panels show the number
of DEGs obtained for the real dataset (a), synthetic dataset with differential gene expres-
sion (b), and synthetic dataset without differential gene expression (c). Symbols are the
same as in Fig. 3 (empty black circles, Median normalization; empty red up triangles,
Quantile normalization; filled green circles, MedianCD normalization; filled blue up tri-
angles, SVCD normalization; empty black down triangles, number of treatment positives
(b)). In each panel, treatments are ordered according to the number of DEGs identified
with SVCD normalization, increasing from left to right.
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Supplementary Figure S3: In the Golden Spike dataset, and without restricting probe
sets to those with signal in all samples (Fig. 8), MedianCD and SVCD normalization also
allowed the best detection of differential gene expression. Both panels display ROC curves,
with the true positive rate versus the false positive rate (a), or the number of true positives
versus the number of false positives (b). Each curve shows the results obtained after
applying the four normalization methods plus Cyclic Loess normalization (same colors and
symbols as in Fig. 8; black curve with empty black circles, Median normalization; red curve
with empty red up triangles, Quantile normalization; green curve with filled green circles,
MedianCD normalization; blue curve with filled blue up triangles, SVCD normalization;
magenta curve with filled magenta diamonds, Cyclic Loess normalization). Dashed curves
with lightly filled symbols, overlapping the response of SVCD normalization, show results
when the list of known negatives was provided to MedianCD, SVCD, and Cyclic Loess
normalization. The two points per normalization method show results when controlling
the false discovery rate (FDR) to be below 0.01 (left point) or 0.05 (right point). Dashed
lines in (b) show references for actual FDR equal to 0.01, 0.05, 0.1, 0.2, or 0.5 (from
left to right). As in Fig. 8, compared to MedianCD and SVCD normalization, the other
normalization methods resulted in notably more severe degradation of the FDR.
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Supplementary Figure S4: In the Golden Spike dataset, and with t-tests instead of limma
analysis (Fig. 8), MedianCD and SVCD normalization also allowed the best detection of
differential gene expression. Both panels display ROC curves, with the true positive
rate versus the false positive rate (a), or the number of true positives versus the number
of false positives (b). Each curve shows the results obtained after applying the four
normalization methods plus Cyclic Loess normalization (same colors and symbols as in
Figs. 8, S3; black curve with empty black circles, Median normalization; red curve with
empty red up triangles, Quantile normalization; green curve with filled green circles,
MedianCD normalization; blue curve with filled blue up triangles, SVCD normalization;
magenta curve with filled magenta diamonds, Cyclic Loess normalization). Dashed curves
with lightly filled symbols, overlapping the response of SVCD normalization, show results
when the list of known negatives was provided to MedianCD, SVCD, and Cyclic Loess
normalization. The two points per normalization method show results when controlling
the false discovery rate (FDR) to be below 0.01 (left point) or 0.05 (right point). Dashed
lines in (b) show references for actual FDR equal to 0.01, 0.05, 0.1, 0.2, or 0.5 (from left to
right). Compared to results obtained with limma analysis (Figs. 8, S3), the degradation
of FDR was slightly less severe with t-tests. MedianCD and SVCD normalization resulted
again in the least degradation of the FDR.
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Supplementary Figure S5: In the Platinum Spike dataset, and without restricting probe
sets to those with signal in all samples (Fig. 9), all normalization methods resulted in
similar detection of differential gene expression, with the exception of Cyclic Loess nor-
malization (magenta curve/symbols), whose number of detected positives was slightly
smaller. Both panels display ROC curves, with the true positive rate versus the false
positive rate (a), or the number of true positives versus the number of false positives
(b). Each curve shows the results obtained after applying the four normalization meth-
ods plus Cyclic Loess normalization (same colors and symbols as in Fig. 9; black curve
with empty black circles, Median normalization; red curve with empty red up triangles,
Quantile normalization; green curve with filled green circles, MedianCD normalization;
blue curve with filled blue up triangles, SVCD normalization; magenta curve with filled
magenta diamonds, Cyclic Loess normalization). Dashed curves with lightly filled sym-
bols show results when the list of known negatives was provided to MedianCD, SVCD,
and Cyclic Loess normalization. The two points per normalization method show results
when controlling the false discovery rate (FDR) to be below 0.01 (left point) or 0.05 (right
point). Dashed lines in (b) show references for actual FDR equal to 0.01, 0.05, 0.1, 0.2,
or 0.5 (from left to right). As in Fig. 9, the difference between normalization methods
in the resulting degradation of the FDR was smaller for this dataset than for the Golden
Spike dataset (Figs. 8, S3, S4).
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Supplementary Figure S6: In the Platinum Spike dataset, and with t-tests instead
of limma analysis (Fig. 9), all normalization methods resulted in similar detection of
differential gene expression, with MedianCD and SVCD normalization being marginally
better. Both panels display ROC curves, with the true positive rate versus the false
positive rate (a), or the number of true positives versus the number of false positives
(b). Each curve shows the results obtained after applying the four normalization methods
plus Cyclic Loess normalization (same colors and symbols as in Figs. 9, S5; black curve
with empty black circles, Median normalization; red curve with empty red up triangles,
Quantile normalization; green curve with filled green circles, MedianCD normalization;
blue curve with filled blue up triangles, SVCD normalization; magenta curve with filled
magenta diamonds, Cyclic Loess normalization). Dashed curves with lightly filled symbols
show results when the list of known negatives was provided to MedianCD, SVCD, and
Cyclic Loess normalization. The two points per normalization method show results when
controlling the false discovery rate (FDR) to be below 0.01 (left point) or 0.05 (right
point). Dashed lines in (b) show references for actual FDR equal to 0.01, 0.05, 0.1, 0.2,
or 0.5 (from left to right). Compared to results obtained with limma analysis (Figs. 9,
S5), and in contrast to the Golden Spike dataset (Figs. 8, S3, S4), the degradation of the
FDR was slightly more severe with t-tests in this dataset.
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Legends of Supplementary Movies
Supplementary Movie S1. Example of one within-condition Standard-Vector normal-
ization, for the real (E. crypticus) dataset. The movie shows the 14 steps of the conver-
gence of Standard-Vector normalization performed for the condition Ag.NM300K.EC20.3d
(exposure to Ag NM300K nanoparticles, with an EC50 dose for three days). Left panels
show a subset of 10,000 randomly-chosen sample standard vectors, with one gray line
per gene, in the plane of residual vectors, i.e. the plane perpendicular to the vector of
coordinates (1, 1, 1). The lines labeled s1–s3 indicate the projection of the axes onto this
plane, the number 1–3 being the sample number. The red line is the estimated vector
of normalization factors at each step, with length ‖offset‖, which results from the bias
of the standard vectors towards that direction. Right panels show the polar distribution
of vector angles (black solid curve), compared to the distribution of vector angles after
all six possible permutations of the sample labels (blue dashed curve). The Watson U2
statistic provides a measure of the difference between both distributions. In the initial
step, there is a large bias towards the first and second sample, compared to the third one.
The bias is reduced in each step by subtracting the normalization factor estimate, which
makes the distribution of standard vectors more permutationally symmetric and with a
correspondingly smaller U2. After convergence in 14 steps, there is no detectable bias
left.
Supplementary Movie S2. Example of one within-condition Standard-Vector normal-
ization, for the synthetic dataset without differential gene expression. The movie displays
the Standard-Vector normalization performed for the condition Ag.NM300K.EC20.3d,
on the synthetic dataset generated with the standard normal N (0, 1) as base distribu-
tion. Format and labels are the same as in Supplementary Movie S1. Note the uniform
distribution of angles after normalizing, which corresponds to a parametric family of prob-
ability distributions with spherical symmetry. The corresponding movie for the synthetic
dataset with differential gene expression is virtually identical, given that standard vectors
are independent of sample averages.
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Supplementary Movie S3. Example of one within-condition Standard-Vector normal-
ization, for synthetic log-normal data. The movie shows the standard-vector normalization
performed for the condition Ag.NM300K.EC20.3d, on a synthetic dataset generated in
the same way as that of Supplementary Movie S2, except for using as base distribution the
log-normal logN (0, 0.52), which has large positive skewness (≈ 1.75). Format and labels
are the same as in Supplementary Movies S1, S2. Note that the distribution of standard
vector angles after normalizing is not uniform, but it has permutation symmetry.
Supplementary Movie S4. Identification of no-variation genes (non-differentially ex-
pressed genes) for the real (E. crypticus) dataset. The movie shows the 27 steps of the
corresponding between-condition normalization, with SVCD normalization. Both panels
show the empirical distribution function of p-values obtained from ANOVA tests on ex-
pression levels, per gene and grouped by experimental condition. The left panel shows the
complete interval [0, 1], while the right panel depicts the interval close to 1 where the first
goodness-of-fit (GoF) test was not rejected. The black portion of the distribution corre-
sponds to p-values at which the GoF test was rejected, the big black circle indicates the
first p-value at which the GoF test was not rejected, and the red portion shows the range
of p-values whose genes, as a result, were identified as no-variation genes. The dashed blue
line and the dotted blue line indicate, respectively, the theoretical distribution function
of the uniform distribution and the threshold of the one-sided Kolmogorov-Smirnov test
(α = 0.001, n equal to the number of p-values for the first GoF test that was not rejected).
Convergence criteria was met from steps 18 to 27. These last ten steps ensured stability
of the detected set of no-variation genes, by cumulative intersection of the successive sets
identified, each one with #H0 no-variation genes, as shown. The resulting final set had
974 no-variation genes.
Supplementary Movie S5. Identification of no-variation genes for the synthetic dataset
with differential gene expression. The movie shows the 15 steps of the corresponding
between-condition normalization, with SVCD normalization. Format and labels are the
same as in Supplementary Movie S4. Note the similarity with the behavior observed for
the real dataset (Supplementary Movie S4).
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Supplementary Movie S6. Identification of no-variation genes for the synthetic dataset
without differential gene expression. The movie shows the 14 steps of the corresponding
between-condition normalization, with SVCD normalization. Format and labels are the
same as in Supplementary Movies S4, S5. Note that the distribution of p-values at
convergence (steps 5–14) is uniform in the whole interval [0, 1], up to the level detected
by the goodness-of-fit test. This corresponds to a dataset with no differentially expressed
genes.
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S1 Vectorial representation of sample data
Let x1, . . . , xn be the samples of n independent and identically distributed random vari-
ables X1, . . . , Xn. Let us represent the samples x1, . . . , xn with the Rn column vector
x = (x1, . . . , xn)
′, and let us denote the sample mean by x¯ =
∑n
i=1 xi/n.
Let us define the Rn → Rn vectorial operators mean ( · ) and residual ( ·˜ ), respectively, as
x = ( x¯, . . . , x¯ )′ = x¯1, (13)
x˜ = x− x = x− x¯1, (14)
1 being the all-ones column vector of dimension n.
Thus, any sample vector x ∈ Rn can be decomposed as
x = x + x˜. (15)
The mean vector x contains the sample mean, while the residual vector x˜ carries the
sample variation around the mean.
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The vectorial operators mean (13) and residual (14) are linear.
Proposition. For any two sample vectors x,y ∈ Rn and any two numbers α, β ∈ R,
αx + βy = αx + βy, (16)
˜αx + βy = αx˜ + βy˜. (17)
Proof. Let us denote x = (x1, . . . , xn)
′ and y = (y1, . . . , yn)′.
αx + βy =
∑n
i=1 (αxi + βyi)
n
1 = α
∑n
i=1 xi
n
1 + β
∑n
i=1 yi
n
1 = αx + βy,
˜αx + βy = αx + βy − αx + βy = αx + βy − (αx + βy),
= α(x− x) + β(y − y) = αx˜ + βy˜. 
An essential property of the mean and residual vectors is that they belong to subspaces
that are orthogonal complements [Eaton, 2007]. Hence, for any sample vector x ∈ Rn,
the mean vector x belongs to the subspace of dimension 1 spanned by the unit vector
1̂ = 1/
√
n, while the residual vector x˜ belongs to the (n − 1)-dimensional hyperplane
orthogonal to 1̂.
The lengths of the mean vector and residual vector are equal, up to a scaling factor, to the
sample mean and sample standard deviation, respectively. For a set of samples x1, . . . , xn,
where n ≥ 2, let us denote the sample mean as before by x¯ = ∑ni=1 xi/n, and the sample
variance as s2x =
∑n
i=1(xi − x¯)2/(n − 1). Then, the lengths of the mean and residual
vectors obtained from the sample vector x = (x1, . . . , xn)
′ are
‖x‖ =
√
n x¯2 =
√
n |x¯|, (18)
‖x˜‖ =
√√√√ n∑
i=1
(xi − x¯)2 =
√
n− 1 sx. (19)
Finally, let us define the standard vector of the sample vector x = (x1, . . . , xn)
′ (n ≥ 2),
as
stdvec(x) =
√
n− 1 x˜‖x˜‖ , (20)
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whenever x˜ 6= 0, or otherwise as stdvec(x) = 0. 0 is the all-zeros column vector of
dimension n.
For a given number of samples n, all the non-zero standard vectors belong to the (n− 2)-
sphere of radius
√
n− 1, embedded in the (n− 1)-dimensional hyperplane perpendicular
to 1̂. Besides, all the components of a standard vector are equal to the corresponding
standardized samples,
√
n− 1 x˜i‖x˜‖ =
xi − x¯
sx
. (21)
For the degenerate case of having only two samples (n = 2), the only possible values of a
non-zero standard vector are ±( 1/√2, −1/√2 )′.
S2 Linear decomposition of the normalization problem
Let us consider a gene expression dataset, with g genes and c experimental conditions.
Each condition k has sk samples. The total number of samples is s =
∑c
k=1 sk.
Let us denote the observed expression level of gene j in the sample i of condition k by y
(k)
ij .
We assume that the observed level y
(k)
ij is equal, in the usual log2-scale, to the addition of
the normalization factor a
(k)
i to the true gene expression level x
(k)
ij ,
y
(k)
ij = x
(k)
ij + a
(k)
i . (22)
Solving the normalization problem amounts to finding the normalization factors a
(k)
i from
the observed values y
(k)
ij . The normalization factors can be understood as sample-wide
changes in the concentration of mRNA molecules by multiplicative factors equal to 2a
(k)
i .
These changes are caused by technical reasons in the assay and are independent of the
biological variation in the true levels x
(k)
ij .
Let us represent the true and observed expression levels, x
(k)
ij and y
(k)
ij , of gene j in the
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samples i = 1 . . . sk of condition k, by the sk-dimensional vectors
x
(k)
j = ( x
(k)
1j , . . . , x
(k)
skj
)′, (23)
y
(k)
j = ( y
(k)
1j , . . . , y
(k)
skj
)′. (24)
Let us also represent the unknown normalization factors of condition k by the sk-dimensional
vector
a(k) = ( a
(k)
1 , . . . , a
(k)
sk
)′. (25)
From (22)–(25), the normalization problem can be written in vectorial form as
y
(k)
j = x
(k)
j + a
(k). (26)
Applying the vectorial operators mean (13) and residual (14), we obtain
y
(k)
j = x
(k)
j + a
(k), (27)
y˜
(k)
j = x˜
(k)
j + a˜
(k). (28)
The residual-vector equations (28) correspond to the c within-condition normalizations.
Each within-condition normalization uses the equations (28) particular to a condition k,
for the subset of genes Gk ⊆ {1, . . . , g} that have expression level available and of enough
quality in that experimental condition.
Let us denote the condition means for each gene as
x
(k)
j =
∑sk
i=1 x
(k)
ij
sk
, (29)
y
(k)
j =
∑sk
i=1 y
(k)
ij
sk
, (30)
a(k) =
∑sk
i=1 a
(k)
i
sk
, (31)
so that
x
(k)
j = x
(k)
j 1sk , (32)
y
(k)
j = y
(k)
j 1sk , (33)
a(k) = a(k)1sk , (34)
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1sk being the all-ones column vector of dimension sk.
Then, the mean-vector equations (27) can be written as
y
(k)
j 1sk = x
(k)
j 1sk + a
(k)1sk , (35)
so they reduce to the scalar equations
y
(k)
j = x
(k)
j + a
(k). (36)
Let us define the vectors of conditions means as
x∗j = (x
(1)
j , . . . , x
(c)
j )
′, (37)
y∗j = ( y
(1)
j , . . . , y
(c)
j )
′, (38)
a∗ = ( a(1), . . . , a(c) )′, (39)
and let us express the condition-mean equations in vectorial form as
y∗j = x
∗
j + a
∗. (40)
Applying again the mean and variance operators, we obtain
y∗j = x
∗
j + a
∗, (41)
y˜∗j = x˜
∗
j + a˜
∗. (42)
The residual-vector equations on condition means (42) correspond to the single between-
condition normalization, in a similar way as (28) do for the each of the within-condition
normalizations. There is one equation (42) per gene. The only equations used in the
between-condition normalization are those of the subset of genes G∗ ⊆ {1, . . . , g} that
show no evidence of variation across experimental conditions, according to a statistical
test.
Given that a∗ = a∗1c, (41) has the only unknown a∗. The meaning of a∗ is a conversion
factor between the scale the true and observed expression levels. This factor depends on
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the technology used to measure the expression levels and finding it is out of the scope of
the normalization problem. Therefore, without loss of generality, we assume a∗ = 0, so
a∗ = 0c, (43)
a∗ = a˜∗. (44)
The solution of the between-condition normalization, a˜∗, allows to find the mean vectors
of the normalization factors a(k), via (34), (39) and (44). The within-condition normaliza-
tions yield the residual vectors a˜(k). The complete solution to the normalization problem
is finally obtained, for each condition k, with
a(k) = a(k) + a˜(k). (45)
Thus, the original normalization problem (26) has been divided in c+1 normalization sub-
problems on residual vectors, stated by (28) and (42). In fact, this linear decomposition
is possible for any partition of the set of s samples. The choice of the partition as the one
defined by the experimental conditions is motivated by the need to control the biological
variation among the genes used in each normalization. All the c + 1 normalizations face
the same kind of normalization of residuals problem, which we define in general as follows.
Normalization of Residuals Problem. Let yij be the i-th observed value of feature
j, in a dataset with n ≥ 2 observations for each of the m features. The observed values
yij are equal to the true values xij plus the normalization factors ai, which are constant
across features. In vectorial form, there are m equations
yj = xj + a, (46)
where the vectors belong to Rn. As a consequence
y˜j = x˜j + a˜. (47)
Solving the normalization of residuals problem amounts to finding the residual vector of
normalization factors a˜ from the observed residual vectors y˜j. In the within-condition
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normalizations, the features are gene expression levels, with one observation per sample
of the corresponding experimental condition. In the between-condition normalization, the
features are means of gene expression levels, with one observation per condition.
There is, however, an additional requirement imposed by the methods with which we
propose to solve the between-condition normalization. We would like to consider the
condition means x
(k)
j in (36) as sample data across conditions. This only holds when all
the conditions have the same number of samples. Otherwise, we balance the condition
means so that they result from the same number of samples in all conditions, according
to the procedure described in the following.
Let s∗ be the minimum number of samples across conditions, s∗ = min{s1, . . . , sc}. Let
S(k)j be independent random samples (without replacement) of size s∗ from the set of
indexes {1, . . . , sk}, with one sample per gene j and condition k. Then, the balanced
condition means are defined as
x
(k)∗
j =
∑
i∈S(k)j
x
(k)
ij
s∗
, (48)
y
(k)∗
j =
∑
i∈S(k)j
y
(k)
ij
s∗
, (49)
a
(k)∗
j =
∑
i∈S(k)j
a
(k)
i
s∗
. (50)
From (22), the balanced condition means verify a relationship similar to (36),
y
(k)∗
j = x
(k)∗
j + a
(k)∗
j . (51)
Moreover, the average of a
(k)∗
j across the sampling subsets S(k)j is equal to the unknown
a(k). This implies that (51) are, on average, equivalent to (36). Hence, we use the following
vectors of balanced conditions means
x∗j = (x
(1)∗
j , . . . , x
(c)∗
j ), (52)
y∗j = ( y
(1)∗
j , . . . , y
(c)∗
j ), (53)
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instead of (37), (38), in order to build the condition-mean equations (40). This balancing
of the condition means is only required when the experimental conditions have different
number of samples.
S3 Permutation invariance of multivariate data
Let xij and yij be, respectively, the true and observed values of a dataset with n observa-
tions of m features, as defined in the normalization of residuals problem above.
We have assumed that the n true values x1j, . . . , xnj of feature j are samples of independent
and identically distributed random variables X1j, . . . , Xnj. These random variables can
be represented with the random vector Xj = (X1j, . . . , Xnj)
′, carried by the probability
space (Ω,F ,P) and with induced space (Rn,Bn,P). Let us define the random vectors Xj
and X˜j with the vectorial operators mean (13) and residual (14), respectively,
Xj =
n∑
i=1
Xij
n
, (54)
Xj = (Xj, . . . , Xj )
′ = Xj1, (55)
X˜j = Xj −Xj = Xj −Xj1. (56)
Xj = Xj + X˜j holds for any random vector Xj, as well as the other properties presented
above. Let us assume that E( ‖Xj‖ ) <∞ and that P( ‖X˜j‖ = 0 ) = 0, which imply that
X˜j/‖X˜j‖ has length 1 almost surely.
The standard random vector
√
n− 1 X˜j/‖X˜j‖ is a pivotal quantity, where the location
(mean) and scale (standard deviation) of feature j have been removed. The probability
distribution of X˜j/‖X˜j‖ across the remaining degrees of freedom over the unit (n −
2)-sphere is governed by the parametric family of the random variables X1j, . . . , Xnj.
Moreover, the independence and identity of distribution across the n observations implies
that the distribution of Xj is exchangeable, i.e. invariant with respect to permutations
of the observation labels. As a result, X˜j/‖X˜j‖ is also permutation invariant, which
geometrically corresponds to symmetries with respect to the n! permutations of the axes
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in the n-dimensional space of random vectors, projected onto the (n − 1)-dimensional
hyperplane of residual vectors.
Residual vectors and standard vectors have been widely studied, especially in relation
to elliptically symmetric distributions and linear models [Fang et al., 1990; Gupta et al.,
2013], and to the invariances of probability distributions [Kallenberg, 2005]. Here, we
consider these vectors from the viewpoint of the problem of normalizing multivariate
data, and its relationship with permutation invariance.
It is well know that, for a multivariate distribution with independent and identically
distributed components, the expected value of the standard vector is zero [Eaton, 2007],
given that it is so for each component. We prove this here for completeness, and to show
that it is also a necessary consequence of the permutation invariance of the distribution.
Proposition. The expected value of any true (i.e. without normalization issues) stan-
dard vector is zero. If the n ≥ 2 samples of feature j are independent and identically
distributed, then
E
(
√
n− 1 X˜j
‖X˜j‖
)
= 0. (57)
Proof. Let Pn be the set of all the permutation matrices in Rn×n. Then, for any P ∈ Pn,
X˜j/‖X˜j‖ is equal in distribution to P X˜j/‖X˜j‖. This implies that
E
(
X˜j
‖X˜j‖
)
= E
(
P
X˜j
‖X˜j‖
)
= P E
(
X˜j
‖X˜j‖
)
.
The only vectors that are invariant with respect to all possible permutations are those
that have all components identical. Therefore, E( X˜j/‖X˜j‖ ) = α1̂, with α ∈ R. However,
X˜′j1̂ = 0, so that α = E( X˜j/‖X˜j‖ )′ 1̂ = 0. Hence E( X˜j/‖X˜j‖ ) = 0. 
For each true random vector Xj, there is an observed random vector Yj = Xj + A,
where A is the random vector of normalization factors. The random vectors Xj and A
are independent, representing biological and technical variation, respectively. Therefore,
and without loss of generality, we assume in what follows a fixed vector of normalization
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factors a, i.e. we condition on the event {A = a }. We also assume that P( ‖Y˜j‖ = 0 ) = 0,
which implies that Y˜j/‖Y˜j‖ has length 1 almost surely.
In contrast to the true standard vector
√
n− 1 X˜j/‖X˜j‖, the observed standard vector
√
n− 1 Y˜j/‖Y˜j‖ is biased toward the direction of a˜, with the result that the expected
value is not zero.
Proposition. If the n ≥ 2 samples of feature j are independent and identically distributed,
whenever a˜ 6= 0,
E
(
√
n− 1 Y˜j
‖Y˜j‖
)
6= 0. (58)
When n = 2, there is the additional requirement that P( ‖X˜i‖ < ‖a˜‖ ) > 0. This threshold
of detection only occurs for the degenerate case of n = 2.
Proof. Let us consider the projection of Y˜j/‖Y˜j‖ on a˜, compared to the projection of
X˜j/‖X˜j‖.
When the vectors X˜j and a˜ are collinear,
X˜′j a˜
‖X˜j‖ ‖a˜‖
= ±1, and Y˜
′
j a˜
‖Y˜j‖ ‖a˜‖
= ±1,
with
Y˜′j a˜
‖Y˜j‖ ‖a˜‖
≥ X˜
′
j a˜
‖X˜j‖ ‖a˜‖
.
This is the only case when n = 2. The additional requirement ensures that, for n = 2,
P
(
Y˜′j a˜
‖Y˜j‖ ‖a˜‖
>
X˜′j a˜
‖X˜j‖ ‖a˜‖
)
> 0,
which implies
E
(
Y˜′j a˜
‖Y˜j‖ ‖a˜‖
)
> E
(
X˜′j a˜
‖X˜j‖ ‖a˜‖
)
.
Otherwise, when n > 2 and the vectors X˜j and a˜ are not collinear, they lie on a plane.
The vector Y˜j = X˜j + a˜ is the diagonal of the parallelogram defined by X˜j and a˜. Hence
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the angle between Y˜j and a˜ is strictly less than the angle between X˜j and a˜, so the cosine
of the angle is strictly greater. Thus,
Y˜′j a˜
‖Y˜j‖ ‖a˜‖
>
X˜′j a˜
‖X˜j‖ ‖a˜‖
.
Due to the permutation symmetries in the distribution of X˜j/‖X˜j‖, when n > 2 the
vector X˜j has non-zero probability of being not collinear with a˜, i.e. P( |X˜′j a˜| < 1 ) > 0.
Therefore,
P
(
Y˜′j a˜
‖Y˜j‖ ‖a˜‖
>
X˜′j a˜
‖X˜j‖ ‖a˜‖
)
> 0,
which again implies
E
(
Y˜′j a˜
‖Y˜j‖ ‖a˜‖
)
> E
(
X˜′j a˜
‖X˜j‖ ‖a˜‖
)
.
Finally, ∥∥∥∥∥E
(
Y˜j
‖Y˜j‖
)∥∥∥∥∥ ≥ E
(
Y˜j
‖Y˜j‖
)′
a˜
‖a˜‖ > E
(
X˜j
‖X˜j‖
)′
a˜
‖a˜‖ = 0. 
As a consequence, the normalization of residuals problem may be restated as the problem
of finding the normalization factors a˜ from the observed vectors y˜j, such that the standard
vectors
√
n− 1 (y˜j − a˜)/‖y˜j − a˜‖ are invariant against permutations of the observation
labels. Or equivalently, such that the standard vectors
√
n− 1 (y˜j − a˜)/‖y˜j − a˜‖ have
zero mean. The following property provides an approach to the solution.
Proposition. Whenever a˜ 6= 0, the component of the expected value of Y˜j/‖Y˜j‖ parallel
to a˜ verifies
0 < E
(
Y˜j
‖Y˜j‖
)′
a˜
‖a˜‖ < E
(
1
‖Y˜j‖
)
‖a˜‖. (59)
As in (58), when n = 2 we also assume that P( ‖X˜j‖ < ‖a˜‖ ) > 0.
Proof. The first inequality holds from the previous proof. Concerning the second inequal-
ity, let us consider
Y˜′j a˜
‖Y˜j‖ ‖a˜‖
=
(X˜j + a˜)
′ a˜
‖X˜j + a˜‖ ‖a˜‖
=
‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
+
‖a˜‖
‖Y˜j‖
.
86
We need to prove that the first term on the RHS has negative expected value. Let us
decompose this term into the positive and negative parts,
‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
=
(
‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
)+
−
(
‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
)−
,
where X+ = max(X, 0) and X− = −min(X, 0).
Because ‖X˜j + a˜‖2 = ‖X˜j‖2 + ‖a˜‖2 + 2X˜′ja˜,(
‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
)+
≤
 ‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜′j a˜
‖X˜j‖ ‖a˜‖
+ ,
(
‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
)−
≥
 ‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜′j a˜
‖X˜j‖ ‖a˜‖
− .
These inequalities are identities when X˜′j a˜ is of opposite sign to ( · )±, or when X˜′j a˜ = 0.
Because of the permutation symmetries of X˜j/‖X˜j‖, it follows that P( X˜′j a˜ 6= 0 ) > 0,
which implies
P
( ‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
)+
<
 ‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜′j a˜
‖X˜j‖ ‖a˜‖
+  > 0,
P
( ‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
)−
>
 ‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜′j a˜
‖X˜j‖ ‖a˜‖
−  > 0,
and hence
E
((
‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
)+ )
< E
 ‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜′j a˜
‖X˜j‖ ‖a˜‖
+  ,
E
((
‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
)− )
> E
 ‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜′j a˜
‖X˜j‖ ‖a˜‖
−  .
For any permutation matrix P ∈ Pn,
‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
=
‖P X˜j‖√
‖P X˜j‖2 + ‖a˜‖2
surely,
X˜j
‖X˜j‖
= P
X˜j
‖X˜j‖
in distribution,
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so that
‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜j
‖X˜j‖
= P
‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜j
‖X˜j‖
in distribution,
which together with  ‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜j
‖X˜j‖
′ 1̂ = 0 surely,
implies, as in (57), that
E
 ‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜j
‖X˜j‖
 = 0.
Therefore,
E
 ‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜′j a˜
‖X˜j‖ ‖a˜‖
+  = E
 ‖X˜j‖√
‖X˜j‖2 + ‖a˜‖2
X˜′j a˜
‖X˜j‖ ‖a˜‖
−  .
Back to the initial expected values, it follows that
E
((
‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
)+ )
< E
((
‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
)− )
,
which implies
E
(
‖X˜j‖
‖X˜j + a˜‖
X˜′j a˜
‖X˜j‖ ‖a˜‖
)
< 0. 
The Gaussian multivariate distribution, among others, has spherical symmetry besides
permutation symmetry. For parametric families with spherical symmetry, the true stan-
dard vector
√
n− 1 X˜j/‖X˜j‖ has uniform distribution over the (n−2)-sphere. As a result,
the components of Y˜j/‖Y˜j‖ perpendicular to a˜ are antisymmetric with respect to the di-
rection of a˜, so that they cancel out in expectation. That is, for parametric families with
spherical symmetry, and as long as a˜ 6= 0,
E
(
Y˜j
‖Y˜j‖
)
= λa˜, with 0 < λ < E
(
1
‖Y˜j‖
)
. (60)
88
S4 Standard-vector normalization
The properties (59), (60) suggest the use of
b̂ =
m∑
j=1
y˜j
‖y˜j‖
m∑
j=1
1
‖y˜j‖
(61)
to approximate the unknown residual vector of normalization factors a˜. The following
iterative method implements this approach to solve the normalization of residuals problem.
Let us define the following recursive sequence, where each step t comprises m vectors ŷ
(t)
j
(j ∈ {1, . . . ,m}) and one vector b̂(t),
ŷ
(0)
j = y˜j, (62)
ŷ
(t)
j = ŷ
(t−1)
j − b̂(t−1), for t ≥ 1, (63)
b̂(t) =
m∑
i=1
ŷ
(t)
j
‖ŷ(t)j ‖
m∑
i=1
1
‖ŷ(t)j ‖
, for t ≥ 0. (64)
We assume that ŷ
(t)
j 6= 0n, for all j ∈ {1, . . . ,m} and all t ≥ 0. Nonetheless, an imple-
mentation of this algorithm benefits from trimming out a small fraction (e.g. 1%) of the
features with lesser ‖ŷ(t)j ‖ in (64), in order to avoid numerical singularities.
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Let us write ŷ
(t)
j as a function of the unknowns x˜j and a˜. For any t ≥ 1,
ŷ
(t)
j = ŷ
(t−1)
j − b̂(t−1), (65)
= ŷ
(t−2)
j − b̂(t−2) − b̂(t−1), (66)
... (67)
= ŷ
(0)
j −
t−1∑
r=0
b̂(r), (68)
= y˜j −
t−1∑
r=0
b̂(r), (69)
= x˜j + a˜−
t−1∑
r=0
b̂(r). (70)
Note that (70) is also valid for t = 0.
Let us also define the vectors â(t), for t ≥ 0, which describe the vector of normalization
factors still to be removed at step t,
â(t) = a˜−
t−1∑
r=0
b̂(r), (71)
so that, by (70), for t ≥ 0,
ŷ
(t)
j = x˜j + â
(t). (72)
Therefore, the recursive sequence (62)–(64) faces a new, weaker normalization of residuals
problem at each step t, with true residual vectors x˜j, observed residual vectors ŷ
(t)
j and
unknown normalization factors â(t). The step t results in the estimation of normalization
factors b̂(t), which are removed from ŷ
(t)
j , generating the next step. At the beginning,
ŷ
(0)
j = y˜j and â
(0) = a˜.
At convergence, limt→∞ b̂(t) = 0. Equations (57), (58), (64) imply that, in such a case,
limt→∞ ŷ
(t)
j = x˜j and
∑∞
t=0 b̂
(t) = a˜. Convergence is optimal when the parametric family
of the m features has spherical symmetry, Gaussian being the most prominent case. Oth-
erwise, the more uniform the distribution of standard vectors
√
n− 1 x˜j/‖x˜j‖ is on the
(n− 2)-sphere, the faster the sequence (62)–(64) converges. See examples of convergence
in Supplementary Movies S1–S3.
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S5 Identification of no-variation genes
Let us consider a gene expression dataset, with g genes and c experimental conditions.
Each condition k has sk samples. The total number of samples is s =
∑c
k=1 sk. Let us
assume that c ≥ 2 and that sk ≥ 2, for all conditions k ∈ {1, . . . , c}. Let us also assume
that, among the g genes, there is a fraction pi0 of non-differentially expressed genes (non-
DEGs), with 0 ≤ pi0 ≤ 1, while the remaining fraction 1− pi0 comprises the differentially
expressed genes (DEGs) [Storey and Tibshirani, 2003].
Let us consider the usual ANOVA test comparing average expression levels across con-
ditions, gene-by-gene. Under the null hypothesis of a non-DEG, the corresponding F -
statistic follows the F -distribution with c − 1 and s − c degrees of freedom. The test of
this hypothesis yields a p-value pj for each gene j ∈ {1, . . . , g}. The obtained p-values pj
follow a probability distribution that can be considered as the mixture of two probability
distributions, F0 and F1, for the non-DEGs and the DEGs, respectively [Storey, 2003].
The fraction pi0 of non-DEGs follows the uniform distribution on the interval [0, 1],
F0(p) = p, (73)
while the fraction 1− pi0 of DEGs follows a distribution that verifies, for any p ∈ (0, 1),
F1(p) > p, (74)
and the mixture distribution is
F (p) = pi0F0(p) + (1− pi0)F1(p). (75)
Let us further assume that there exists a p∗, with 0 < p∗ < 1, such that F1(p) = 1 for
every p ≥ p∗. In other words, all DEGs have p-value pj from the ANOVA test such that
pj ≤ p∗, while only some genes among the non-DEGs have p-value with pj > p∗. This
implies that the mixture distribution of p-values is uniform on the interval [p∗, 1],
F (p) = pi0p+ 1− pi0, for p∗ ≤ p ≤ 1, (76)
f(p) = pi0, for p
∗ < p < 1. (77)
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On the other hand, for any set of n samples x(1) ≤ x(2) ≤ · · · ≤ x(n) obtained from n
independent and identically distributed uniform random variables on the interval [a, b], all
the distances between consecutive ordered samples (including boundaries), x(1)−a, x(2)−
x(1), . . . , x(n) − x(n−1), b− x(n), obey the same distribution [Feller, 1971]. Then, it can be
realized that, for any j such that 2 ≤ j ≤ n−1, the two subsets of samples x(1), . . . , x(j−1)
and x(j+1), . . . , x(n) follow uniform distributions on the intervals [a, x(j)] and [x(j), b], re-
spectively.
Based on these facts, to identify no-variation genes we propose finding the minimum p(j),
from the ordered sequence of p-values p(1) ≤ p(2) ≤ · · · ≤ p(g), such that a goodness-of-fit
test for the uniform distribution on the interval [p(j), 1], performed on p(j+1), . . . , p(g), is
not rejected. As a result, the genes corresponding to the p-values p(j), p(j+1), . . . , p(g) are
considered as no-variation genes.
Given the concavity of F (p), the goodness-of-fit test used is the one-sided Kolmogorov-
Smirnov test on positive deviations of the empirical distribution function.
See Supplementary Movies S4–S6 for examples of this approach to identifying no-variation
genes.
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